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Abstract 
 
IMPAIRED CARDIORESPIRATORY FITNESS FOLLOWING THORACIC 
RADIOTHERAPY 
 
Justin McNair Canada, PhD, RCEP 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2018. 
 
Dissertation Adviser: Antonio Abbate, MD, PhD 
Department of Internal Medicine, Division of Cardiology 
 
Cancer (CA) is the second leading cause of death in the United States preceded 
only by cardiovascular disease (CVD). Over the past 30 years, the 5-year survival rate 
for all cancers combined has increased by more than 20%. This improved survival rate 
is due to early diagnosis and advances in treatment involving a multimodality treatment 
approach that includes radiotherapy [RT] with about half of all CA patients receiving 
some type of RT sometime during the course of their treatment. Cardiotoxicity is one of 
the most important adverse reactions of RT and leads to a meaningful risk of CVD-
related morbidity and mortality. Radiotherapy-related cardiotoxicity is a heterogeneous 
clinical syndrome characterized by symptoms related to impaired cardiac function due 
  
to radiation-injury to one or more cardiac structures. Furthermore, the relative risk of 
CVD increases with increasing incidental radiation dose to the heart.  
There is not a unified consensus on the definition of CA-related cardiotoxicity 
although most trials have focused on changes in resting systolic function, and/or 
development of cardiac symptoms. Commonly used tools to assess cardiac function are 
insensitive to minor injury hence subtle changes may go unnoticed for many years. 
Cardiotoxicity definitions should include a dynamic functional assessment of the CV 
system. This may allow detection of latent CV abnormalities before the precipitous 
decline of resting myocardial function or the development of CV symptomology that may 
impact quality of life.  
Cardiopulmonary exercise testing (CPET) including measurement of peak 
oxygen consumption (VO2) is the gold standard for the assessment of cardiorespiratory 
fitness (CRF). Cardiorespiratory fitness is a strong, independent predictor of mortality, 
CVD-related mortality, HF-related morbidity and mortality, CA-related mortality and may 
be involved in the pathophysiologic link between anti-CA related treatments and the 
increased risk of late CVD events. Emerging evidence indicates CRF may be reduced in 
CA survivors and have utility to detect subclinical cardiotoxicity, but this has not been 
evaluated in CA survivors treated with RT with significant heart involvement. This 
dissertation consists of one literature review and one comprehensive paper that will 
examine the ability of CPET to detect subclinical cardiotoxicity.
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Chapter 1 
 
Introduction 
Cancer (CA) is the second leading cause of death in the United States (U.S.) 
with an estimated 1,688,780 new diagnoses expected in the U.S. this year which is the 
equivalent of 4,600 new cases each day.(1) Breast CA is the most common CA type in 
women involving 252,710 new cases representing 30 percent (%) of all CA in 
women.(2) This translates to an annual incidence of new cases of breast CA of 124.9 
per 100,000 women per year.(3)  
 Despite breast CA being the most common type, the most common cause of CA-
related deaths are cancers of the lung/bronchus representing 25% and 27% of all 
estimated deaths for women and men, respectively.(3) However, over the past 30 
years, the 5-year survival rate for all CA combined has increased by more than 20% at 
similar rates between both sexes. In fact, the 5-year survival rate of women with breast 
CA is now approaching 90%.(2) Currently, there are more than 3.1 million breast CA 
survivors in the U.S.(4) The improved survival rate is due to early diagnosis and 
advances in treatment of involving a multimodality treatment approach that involves 
surgery, systemic therapy (chemotherapy, targeted-therapy, or endocrine therapy [ET]), 
and radiotherapy [RT]. The multimodality treatment of CA although shown to improve 
CA-specific recurrence and mortality is offset with an increased risk of non-CA related 
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morbidity/mortality primarily due to increased cardiovascular disease-related (CVD) 
events.(5)  
Cardiotoxicity, a general term used to describe "toxicity that affects the heart", is 
one of the most important adverse reactions of systemic therapy and RT and leads to a 
meaningful risk of CVD-related morbidity and mortality.(6, 7) Cytotoxic agents, targeted 
therapies, and incidental exposure of the heart to irradiation can all negatively affect the 
CV system and increase CVD risk.(8, 9) This CVD risk is further pronounced in the 
setting of combination therapy whereby systemic agents are used in combination or 
coupled with RT.(10) The reason is that many of these agents reach targets in the 
microenvironment that do not affect only the cancerous tumor. The improving survival of 
patients, particularly breast-CA patients (the largest cohort of CA survivors), justifies the 
use of this multimodality treatment approach, but strategies must be introduced to 
detect, offset and monitor this CVD risk. 
The purpose of this review is to describe current anti-CA treatments, identify 
those with known cardiotoxic side effects, discuss the proposed mechanisms linking 
anti-CA treatments with cardiotoxicity, and review the current detection methods used to 
identify cardiotoxicity in the CA patient. This review will primarily focus on the breast CA 
patient due to their over-representation for both CA diagnosis and survivorship. 
Furthermore, the role of anti-CA treatments on cardiorespiratory fitness (CRF) and its 
determinants is discussed highlighting its potential link to cardiotoxicity. Finally, the 
measurement of CRF variables using cardiopulmonary exercise testing (CPET) is 
reviewed with an emphasis on the potential ability to detect cardiotoxicity in the CA 
patient.   
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I. Anti-Cancer Treatments 
 The American Joint Committee on Cancer (AJCC) has developed a system 
based on clinical and pathologic features to classify patients with CA, define prognosis, 
and determine the best treatment approaches.(11) This staging system characterizes 
patients based on primary tumor (T) size, lymph node (N) involvement, and observance 
of metastasis (M) to classify patients based on the extent of disease and the impact of 
treatments. Tumor size (T) is graded on a 0–4 scale with higher numbers indicating 
larger size and/or invasion into adjacent structures. Node (N) involvement is graded on 
a 0-3 scale based upon CA spread to lymph nodes and the number of nodes involved. 
Metastasis is classified as 0 (no) or 1 (yes) if the CA has spread to other organs. 
Cancers are also staged (0–IV) with higher stages indicating larger tumors or the extent 
of spread according to pathological characteristics based upon tumor size and spread to 
lymph nodes or other organs. These systems allow application of evidence-based 
treatments based on CA subtype and can be used to gauge treatment success with the 
goal of a complete response. Complete response is defined as the absence of invasive 
carcinoma in the breast and axillary nodes.(11) Specific to breast CA, treatment is also 
based on the following clinical and pathological features: menopausal status and patient 
age, stage of disease, grade of the primary tumor, hormone status (estrogen receptor 
(ER+/-) and progesterone receptor (PR+/-) expression), human epidermal growth factor 
type 2 receptor (HER2 +/-) expression, and histologic type.(2) 
 Surgery is considered standard treatment for early, localized, or operable breast 
CA and may include breast-conserving surgery (BCS) referred to as lumpectomy or 
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modified radical mastectomy involving removal of the entire breast. In patients with 
stages I, II, and T3N1 disease the initial management is surgical resection.(12) Breast-
conserving surgery coupled with adjuvant RT provides comparable outcomes in terms 
of disease-specific survival as compared with mastectomy and confers improved quality 
of life thus it is considered the standard of care for early stage breast CA.(13, 14) Breast 
conservation therapy (lumpectomy and RT) provides survival equivalent to mastectomy, 
preserves cosmetic appearance, while providing a similar low risk of CA recurrence in 
the treated breast.(15)  
 More than 50% of breast CA patients receive RT as part of their treatment.(16) 
Radiotherapy can be used alone with curative intent or, more often, is coupled with 
surgery and systemic therapy based on tumor characteristics. When used after BCS, 
RT reduces the risk of local recurrence (LR) by as much as 70%. A recent meta-
analysis of the Early Breast Cancer Trialists Collaborative Group (EBCTCG) in 2011, 
including 10,801 women with a median follow-up period of 9.5 years concluded RT 
proportionally reduced the rate of LR or distant metastases over the first 10-years by 
about half (relative risk = 0.52) and proportionally reduced the rate of breast CA-related 
death by approximately one-sixth.(17) 
 Chemotherapy are systemic agents given as neo-adjuvant therapy (prior to 
primary scheduled therapy; i.e. surgery) or as adjuvant therapy (after primary therapy) 
consisting of multiple cycles of polychemotherapy to reduce the risk of breast CA 
recurrence and provide an additional disease-specific survival benefit.(18) 
Chemotherapy used neo-adjuvantly or adjuvantly is used in the treatment of 
approximately 38% of all breast CA survivors although is used in the majority of other 
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CA types.(3) The most common drugs used for breast CA chemo include 
anthracyclines, taxanes, flouropyrimidines (5-fluorouracil), cyclophosphamide, and 
carboplatin.(19) However, taxane-based and anthracycline-based regimes have shown 
to be superior to cyclophosphamide, 5-fluorouracil, and nonanthracycline-based 
regimens.(18) For breast CA patients who warrant chemo, multiple cycles of adjuvant 
chemo including taxanes and anthracyclines are considered “gold-standard” and as 
such are part of the standard regimen for most patients with node-positive and high-risk 
node-negative tumors.(20) This benefit of chemo has also been realized in women with 
hormone receptor +/-  status regardless of age or menopausal status.(21) However, not 
all patients need chemo as the differences in the absolute risk of recurrence is small in 
patients with small CA or ER+ CA that also receive adjuvant ET.(22) 
 Hormone receptor status appears to be an important predictor of derived-benefit 
from chemo. The ER is present in about 70% of invasive breast CA and 80% of ductal 
carcinoma in situ (DCIS) tumors.(23) Targeted ET with the use of ER modulators or 
aromatase inhibitors (AI) in post-menopausal women may reduce LR following BCS and 
prevent development of new primary breast CA in the contralateral breast.(24) Tumors 
that are ER- benefit substantially from chemo added to ET whereas ER+ tumors do not 
glean as much benefit from the addition of chemo on top of ET.(25)  
 The human epidermal growth factor type-2 receptor (HER2) (found in 20% of 
invasive breast CA) historically has been linked to a higher risk of recurrence, relative 
resistance to ET due to lower levels of ER expression, and resistance to 
cyclophosphamide/methotrexate/5-fluorouracil (CMF)-based chemotherapies.(26) 
However, in 2005 the reports of five randomized trials examining the utility of a targeted 
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therapy using a humanized monoclonal antibody (Trastuzumab) against the HER2 
protein for HER2 overexpressing breast CA demonstrated significant improvements in 
disease-free survival (DFS)(50% average risk reduction) and overall survival (OS).(27–
30) This led to the standardization of Trastuzumab as a treatment for HER2+ breast CA.  
 
Chemotherapy 
 Anthracyclines 
 Anthracyclines (ACT) are anti-CA compounds derived from Streptomyces 
bacteria that are delivered intravenously (IV) and enter cells through passive diffusion. 
They bind to proteasomes in the cytoplasm and are then translocated into the cell 
nucleus. Proteasomes are predominantly located in the nucleus of neoplastic and 
normal proliferative cells. Once ACT enter the nucleus they disassociate from the 
proteasome and bind to deoxyribonucleic acid (DNA).(31) In addition, by binding to 
proteasomes, ACT inhibit protease activity leading to inhibition of protein degradation, 
accumulation of misfolded proteins, and thus induction of apoptosis. The mechanism of 
action appears to be multifactorial including cell DNA intercalation, interaction with DNA 
binding proteins, induction of apoptosis, formation of reactive oxygen species (ROS), 
and anti-angiogenic mechanisms.(32–35) The major drugs used in this class of agents 
for breast CA include Doxorubicin (brand names: Adriamycin, Doxil), Epirubicin (brand 
name: Ellence), Daunorubicin (brand names: Cerubidine, DaunoXome), and 
Mitoxantrone (brand name: Novantrone).(36)  
Taxanes 
 
14 
 
 
 
 Taxanes are a class of diterpenes first extracted from the bark of Pacific yew 
trees.  Taxanes inhibit cell proliferation by blocking mitotic activity through their actions 
on microtubules leading to polymerization, mitotic metaphase inhibition, and spindle 
microtubule rearrangement.(37) Paclitaxel (brand name: Taxol), Docetaxel (brand 
name: Taxotere) are the major taxanes used for the treatment of breast CA.(38) The 
Cancer and Leukemia Group B 9344 report was the first to demonstrate the addition of 
sequential Paclitaxel therapy improved DFS and OS in comparison to 
cyclophosphamide-doxorubicin (AC) chemotherapy.(39) To date, the optimal dosing 
regimen appears to be treatment of 4-cycles every 2-weeks in sequential order following 
ACT/alkylating agent therapy for reducing breast CA recurrence.(40) 
5-Fluorouracil 
The fluoropyrimidine, Fluorouracil or 5-fluorouracil (5-FU) works as an 
antimetabolite to prevent cell proliferation. It primarily inhibits the enzyme thymidylate 
synthase (TS) blocking the thymidine formation required for DNA synthesis.(41) 
Fluorouracil (brand name: Adrucil) is a pyrimidine analog that interferes with DNA and 
RNA synthesis by mimicking the building blocks necessary for synthesis. It can be used 
as a single agent but is most commonly administered via IV in combination with other 
chemotherapy regimens.  
Cyclophosphamide 
Cyclophosphamide is a synthetic alkylating agent chemically related to the 
nitrogen mustards with antineoplastic and immunosuppressive activities. It is the most 
widely used alkylating agent and has antineoplastic activity in a variety of tumors.(42) In 
the liver, cyclophosphamide requires activation by cytochrome P-450 and is then 
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converted to the active metabolites aldophosphamide and phosphoramide mustard, 
which bind to DNA, thereby inhibiting DNA replication and initiating cell death. 
Cyclophosphamide is routinely used in combination with other systemic agents and 
usually administered via IV in divided doses relative to bodyweight. 
 
Carboplatin 
Cis-diamminecyclobutanedicarboxylate platinum or Carboplatin contains a 
platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl 
residue. It is activated intracellularly to form reactive platinum complexes that bind to 
nucleophilic groups such as guanine-cytosine-rich sites in DNA, thereby inducing intra-
strand and inter-strand DNA cross-links, as well as DNA-protein cross-links. These 
carboplatin-induced DNA and protein effects result in apoptosis and cell growth 
inhibition.(43) Carboplatin (brand name: Paraplatin) is usually administered as a rapid 
IV infusion over 30-minutes. In HER2+ breast CA, platinum-based agents exhibit a 
synergistic cytotoxic effect when coupled with anti-HER2 monoclonal antibodies.(44) 
 
Targeted Therapy 
 Targeted therapy is the use of agents that target specific changes in CA cell 
types whereas chemotherapy agents exert their neoplastic effects irrespective of cell 
type. Overexpression of the HER2 receptor protein is present in about one out of five 
women with breast CA and is associated with an aggressive subtype that leads to a 
poor prognosis. Targeting HER2 expression inhibits epidermal growth factors/ HER2 
ligand receptor activity and disrupts the phosphorylation of intracellular tyrosine kinases 
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that regulate cell growth and survival. Trastuzumab (brand name: Herceptin) was the 
first HER2-targeted therapy approved by the Food and Drug Administration (FDA).(45) 
The adjuvant use of Trastuzumab is only known to be effective in tumors with aberrant 
expression of HER2 proteins.(46) Initially approved for use in advanced metastatic 
breast CA, subsequent studies have demonstrated a reduced risk in CA recurrence 
(9.5% decrease) and improved OS (3% improvement) in early-stage breast CA 
following surgery.(47) However, all the trials to date showing benefit have utilized 
Trastuzumab in combination with varying chemotherapy regimens. Optimal treatment 
appears to be for twelve months and can be delivered concurrently or sequentially 
following chemotherapy.(20, 28)  
Pertuzumab, another humanized monoclonal antibody that targets different 
extracellular regions of the HER2 tyrosine kinase receptor and blocks HER2 
dimerization is FDA approved in combination with Trastuzumab and Docetaxel for the 
treatment of HER2+ metastatic breast CA and for neo-adjuvant use prior to surgery in 
HER2+ breast CA. (48) 
 
Endocrine Therapy 
 Endocrine therapy works in breast CA by inhibiting the effects of estrogen and 
progesterone on CA cell growth. They work by inhibiting the body’s ability to produce 
hormones or by interfering with the hormones effects on breast CA cells.(49)   
  
 Estrogen Receptor Modulators 
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 Tamoxifen, an estrogen receptor modulator, works by blocking estrogen 
stimulation of breast CA cells, inhibiting translocation and nuclear binding of the ER. 
This binding inhibits transcriptional activation of estrogen-responsive genes. Tamoxifen 
is the only FDA-approved hormonal agent for the prevention of premenopausal breast 
CA, treatment of DCIS, and the treatment of post-surgical ER+ breast CA.(50, 51) The 
EBCTCG overview on the use of adjuvant Tamoxifen demonstrated administration for 
five-years reduced the annual rate of breast CA recurrence by 41% with a 34% 
reduction in the annual death rate for women with ER+ breast CA.(51) 
   
Aromatase Inhibitors 
 Following menopause, the synthesis of ovarian hormones ceases, but estrogen 
production continues by conversion of androgens by aromatase. Aromatase is the 
enzyme complex involved in the final step of estrogen synthesis by the conversion of 
androgens. Aromatase inhibitors (AI) block the actions of aromatase resulting in 
estrogen depletion and are used for the treatment of estrogen-responsive breast CA in 
postmenopausal women. The American Society of Clinical Oncology (ASCO) guidelines 
on adjuvant ET recommend AI treatment in postmenopausal women as either initial 
therapy or as adjunctive sequential therapy following Tamoxifen.(52) The addition of AI 
in the treatment of postmenopausal ER+ breast CA women results in a modest 
improvement in DFS.(53) 
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Radiation therapy (radiotherapy) 
Radiation therapy is administered to cells either in the form of photons (x-rays 
and gamma rays) or particles (protons, neutrons, and electrons). When photons or 
particles interact with biological materials, ionization takes place. Ionization is the 
process by which an atom or a molecule acquires a negative or positive charge by 
gaining or losing electrons to form ions. Ionizations can directly interact with either 
subcellular structures or water within the cell generating free-radicals. The direct effect 
of radiation is the absorbance of its energy by DNA in chromosomes leading to 
ionizations that induce damage including base damage, single-strand breaks, and 
double-stranded breaks. Free-radicals generated by radiation interact with other 
molecules that possess an unpaired electron and molecules without unpaired electrons 
in their outer-shell and can remove a hydrogen molecule from the DNA to cause 
damage. Radiation can induce DNA damage at three primary points during the cell 
cycle.(12)  
Briefly, the cycle of eukaryotic cells can be separated into four discrete phases: 
the mitotic (M) phase of the cycle corresponds to mitosis, which is usually followed by 
cytokinesis. This phase is followed by the gap 1 (G1) phase, which corresponds to the 
interval gap between mitosis and initiation of DNA replication. During G1, the cell is 
metabolically active and continuously grows but does not replicate its DNA. The 
G1 phase is followed by the synthesis (S) phase, during which DNA replication takes 
place. The completion of DNA synthesis is followed by the gap 2 (G2) phase, during 
which cell growth continues and proteins are synthesized in preparation for mitosis. The 
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cell cycle must progress in a specific order and has checkpoint genes that do not allow 
progression to the next event until earlier events are complete.(54) 
Radiation-induced DNA damage can occur at the border between G1/ S phase, 
intra-S phase, and the border between the G2 phase and mitosis. Cells with intact 
checkpoints that have sustained DNA damage become arrested at the next checkpoint 
in the cell cycle. The G1/S phase and intra-S phase checkpoints inhibit the replication of 
damaged DNA. The G2 phase checkpoint inhibits cells from entering mitosis with 
damaged DNA that is transmitted to its progeny.(49) 
In addition to its direct effects on DNA, radiation also affects cellular membranes. 
Ionizing radiation activates membrane receptor pathways such as epidermal growth 
factor (EGFR) and transforming growth factor beta (TGF-)  that promote DNA damage 
repair and/or cell proliferation.(55) 
The goal of RT is to deliver enough ionizing radiation to the tumor site which can 
result in absorbed dose. Most patients treated with RT, receive high-energy, external 
beam photon therapy. The split-dose repair studies of Elkind et al. have formed the 
basis of fractionated radiotherapy wherein a dose is delivered in fractions.(56) When RT 
is delivered in fractions as opposed to a single dose it prolongs cell survival or tumor 
growth delay. The phase of the cell cycle at the time of RT influences the cell’s inherent 
sensitivity to RT. Cells synchronized in late G1/ early S and G2/M phases are most 
sensitive, whereas cells in the G1 and mid to late S phases are most resistant to RT. If 
cells are given a short time interval between doses, they move from a resistant portion 
of the cell cycle to a more sensitive phase enhancing the tumor response to fractionated 
RT while this response is somewhat protracted in normal tissue. This concept of re-
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assortment is also utilized with systemic agents thus making cells more sensitive to 
treatment when used in combination with fractionated RT.  
External beam photon treatments require high energy (usually 6 to 20 megavolts) 
beams with sufficient fluence to penetrate tissue and reach the tumor. To preserve 
normal tissue and maximize tumor dose received, beams are arranged to enter the 
patient from multiple directions and to intersect at the center of the tumor. Computerized 
treatment planning systems using x-ray or computed tomography (CT) to develop 
patient-specific anatomic models with beam-specific dose deposition properties to 
select beam angles, shapes, and intensities to meet prescribed treatments. Beyond the 
ability to define the primary target volume for the tumor these treatment planning 
systems allow characterization of the dose administered to normal tissues.(49) 
Radiation doses are calculated to maximize tumor control without producing 
unacceptable toxicity. The dose of RT required depends on the tumor type, volume of 
tumor cells, and the use of RT-modifying agents such as chemo. Dose is quantified in 
Gray (Gy) units defined as the absorption of one joule of radiation energy per kilogram 
of matter. The effectiveness of a dose of radiation depends on the fraction given with 
each treatment as well as the time required to complete the course of RT. Standard 
fractionation for RT is defined as 1.8 to 2.25 Gy per fraction per day with a total dose of 
whole breast RT of 45 to 54 Gy in the adjuvant setting. A boost or supplementary 
irradiation whereby a 10 to 16 Gy boost to the tumor bed region is also commonly used 
and provides an additional reduced risk of recurrence in the ipsilateral breast.(57) 
  
 
21 
 
 
 
 
II. Cardiotoxicity of Anti-Cancer Therapies 
There are many recognized adverse cardiovascular (CV) effects of anti-CA 
therapies including heart failure (HF), myocardial ischemia/infarction (MI), hypertension 
(HTN), thromboembolism (VTE), and arrhythmias.(58) Cardiotoxicity related to anti-CA 
treatment is important to recognize as it may have a significant impact on the overall 
prognosis and survival of CA patients. Furthermore, it is likely to remain a significant 
challenge due to the aging of the population of patients with CA and the introduction of 
new CA therapies. The risk of cardiotoxicity needs to be balanced with the benefit of 
evidenced-based therapies to eradicate the CA. Early cardiotoxicity can affect a 
patient’s ability to complete CA treatments while late toxicity may impact CVD mortality 
in the CA survivor. 
The National Cancer Institute proposes the use of the Common Terminology 
Criteria for Adverse Events to define left-ventricular (LV) dysfunction and HF based on 
severity into grades 1 to 5.(59) Grade 1 is defined as asymptomatic with elevations in 
cardiac biomarkers or cardiovascular imaging abnormalities, Grades 2-3 include HF 
symptoms at mild and moderate exertion. Grade 4 includes severe HF symptoms 
requiring hemodynamic support and finally, Grade 5 indicates death. The FDA defines 
ACT-induced cardiotoxicity as >20% decrease in left-ventricular ejection fraction (LVEF) 
when baseline LVEF is normal and >10% when baseline LVEF is not normal.(60) 
There is not a unified consensus on the definition of CA-related cardiotoxicity 
although most trials have focused on changes in resting systolic function, namely LVEF 
and/or development of HF symptoms.(61, 62) However, systemic therapies and RT are 
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known to affect the entire CV system not just resting LVEF. There is a need to expand 
the definition of cardiotoxicity to include direct effects on cardiac structure, diastolic 
function, conduction abnormalities, vascular function, hemodynamics, coagulability, and 
the reserve capacity of the CV system to stress. Cardiotoxicity definitions should include 
a dynamic functional assessment of the CV system in addition to measures of resting 
myocardial function. This may allow detection of latent CV abnormalities before the 
precipitous decline of resting myocardial function or the development of CV 
symptomology that may impact quality of life.(63, 64) 
Cardiotoxicity risk is potentiated by pre-existing CVD risk factors and 
combinations of systemic agents with or without RT.(65) Advanced age, smoking, 
sedentarism, obesity, diabetes mellitus, dyslipidemia, HTN, and prior history of CVD are 
all associated with heightened risk. The “multiple-hit” hypothesis proposed by Jones and 
colleagues infers that at the time of diagnosis breast CA patients already have an 
increased risk of developing CVD which is further heightened by the anti-CA 
treatment.(66) Cardiotoxicity risk factors associated with CA-related treatments include: 
mediastinal RT, systemic cytotoxic agents, ET, and targeted therapies.(65) The next 
section of this review will discuss the cardiotoxicity of anti-CA therapies employed in the 
treatment of the CA patient. 
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Cardiotoxicity due to Chemotherapy 
Anthracyclines 
Anthracyclines have long been known to cause LV dysfunction and HF with an 
incidence in the range of 5-23% of patients.(67) The risk of cardiotoxicity is proportional 
to the cumulative ACT exposure(68), however, the CA response rate is proportional to 
the increased ACT dose, thus creating a conundrum.(69) Cardiotoxicity from ACT is 
heightened when the cumulative dose surpasses 300 milligrams per meter squared 
(mg/m2) of body surface area.(70) There is a 5% risk of developing HF with cumulative 
doses of 400mg/m2 and increases to >25% at doses of 700 mg/m2. In the U.S., the 
combination of polychemotherapy (doxorubicin at 60mg/m2 and cyclophosphamide at 
600 mg/m2) in four cycles (total doxorubicin dose at 240 mg/m2) is commonly employed 
as treatment for early-stage breast-CA. The risk of symptomatic HF is relatively rare at 
this cumulative dose of 240 mg/m2, but asymptomatic CV dysfunction is frequently 
observed, and the incidence of late occurring LV systolic dysfunction is not completely 
known.(71) 
The mechanisms of ACT cardiotoxicity are not completely understood although 
the leading hypothesis is that ACTs increase ROS emission within the mitochondria of 
cardiac myocytes.(72) In this oxidative stress model of cardiotoxicity, ROS causes 
protein/ nucleic acid/ lipid oxidation and leads to cell death/ dysfunction.  
Topoisomerase inhibition by ACTs also appears to be important in the 
development of cardiotoxicity. Topoisomerases are essential enzymes required for DNA 
transcription, replication, or recombination and are expressed in two isoenzymes 
(Top2 and Top2) in humans. The Top2 enzyme demonstrates high levels of 
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expression in rapidly proliferating cells. The Top2 enzyme is predominantly expressed 
in quiescent cells such as myocytes.(73) Inhibition of topoisomerases may be a 
beneficial effect of ACTs in high-expression Top2 cells, but may lead to cardiotoxicity 
in predominant Top2 cells. Mice with deletion of cardiomyocyte Top2 genes are 
protected from doxorubicin-induced cardiotoxity.(74)  
Cardiac progenitor cell loss and dysfunction may also be a mechanism of ACT 
cardiotoxicity.(75) In an animal model of pediatric mice, exposed to doxorubicin at levels 
below acute cardiotoxicity ranges, impaired vascular development with decreased 
coronary branching and reduced capillary density upon examination during adulthood 
was demonstrated.(76) The adult doxorubicin mice when subjected to myocardial 
ischemia developed worse ischemic cardiomyopathy and HF and a reduced ability to 
increase capillary density in the infarct border zone. Furthermore, the adult doxorubicin 
mice demonstrated increased sensitivity to physical stress from high-volume swimming 
with increased cardiac hypertrophy and LV dilatation.(76)  
Anthracycline-induced cardiotoxicity can be grouped into 3 categories by its 
temporal relationship: acute, early, late. Acute cardiotoxicity occurs during infusion or 
within one-week of therapy. The acute cardiotoxicity incidence is low (<1%), can include 
pericarditis and arrhythmias, and usually resolves with discontinuation of therapy. Early 
cardiotoxicity occurs within 3-12 months of treatment with a peak onset of symptoms of 
HF at three-months following completion of therapy. Late cardiotoxicity occurs one to 
several years following treatment where patients may be asymptomatic initially and then 
develop HF symptoms sometimes even decades after the ACT treatment.(77) 
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Taxanes 
Arrhythmias are the most common cardiac abnormality observed with the use of 
taxanes.(78) Asymptomatic bradycardia is observed in up to 30% of patients taking 
Paclitaxel with only 0.1% suffering from serious bradycardias.(78) Taxanes also 
interfere with the metabolism and excretion of ACTs and increase the risk ACT 
cardiotoxicity particularly at higher cumulative ACT doses.(79) Taxane treatment with 
Epirubicin may be less cardiotoxic compared with Doxorubicin.(80) Docetaxel is 
associated with an incidence of 2.3-8% for the development of LV dysfunction.(81) 
 
Fluoropyrimidines 
Fluorouracil is associated with an incidence of cardiotoxicity ranging from 1%-
7.6%.(82) The most common manifestations appear to be ischemic in nature including 
angina and electrocardiogram (ECG) changes that appear more frequently in those with 
underlying CVD.(83) A systematic review of the pathophysiology of 5-FU cardiotoxicity 
demonstrated evidence of: interstitial fibrosis, inflammation in the myocardium, 
hemorrhagic infarction, endothelial damage, increased myocardial energy metabolism, 
depletion of high-energy phosphates, increased superoxide anion levels, reduced 
antioxidant capacity, arterial vasoconstriction, alterations in red blood cell (RBC) 
structure, and increased platelet aggregation/ fibrin formation.(84) Cardiotoxicity usually 
occurs early during treatment and is more common at higher doses and with continuous 
infusions.(85) 
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Cyclophosphamide 
Cyclophosphamide therapy is associated with pericardial effusions, pericarditis, 
and HF which occurs in 7-28% of patients.(60) The risk appears to be dose related 
(>150 milligram per kilogram [mg/kg]) and usually occurs within 1 to 10 days of the first 
dose.(60) Like other systemic agents, additional risk factors include combination with 
ACT and/or RT.(86) 
 
Carboplatin 
Vascular toxicity is one of the most important late consequences of platinum-
based chemotherapy.(87) Cisplatin, another platinum analog is associated with an 
accelerated risk of CVD in men with testicular CA.(88) Mechanistically, Cisplatin is 
associated with mitochondrial membrane depolarization, ultrastructural abnormalities of 
the mitochondria, activation of the endoplasmic reticulum stress response, increased 
Caspase-3 activity, and increased apoptosis.(89) Carboplatin, is preferred over Cisplatin 
in breast CA due to its lower toxicity profile.(90) To date, platinum-based non-ACT 
regimens in clinical trials have not demonstrated a significant signal for the development 
of LV dysfunction.(91)  
 
Targeted Therapies – Trastuzumab 
The HER2/neu oncogene encodes a transmembrane tyrosine kinase receptor 
and shares a very similar structure to the epidermal growth factor receptor. The HER2 
gene is involved in embryonic heart development and in the adult, is involved in cardio-
protection.(92) The HER2 signaling is involved in growth, survival, and inhibition of 
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apoptosis in cardiac myocytes. In situations of biomechanical stress, a ligand growth 
factor named neureregulin binds to HER2 to activate the phosphatidylinositide 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) cell survival pathways.(93) 
Trastuzumab, a humanized monoclonal antibody for the HER2 receptor disrupts 
signaling between neureregulin and the HER2 receptor. This may trigger a decline in 
myocardial function because of its effects on cardiomyocyte neureregulin-HER2 
receptor function. It is believed that exposure to Trastuzumab results in a loss of 
contractility due to cellular stunning rather than cardiomyocyte death.(94)  
 Breast CA patients taking HER2-antagonists also experience increased levels of 
norepinephrine with concomitant increases in blood pressure (BP) and heart rate 
(HR).(95) Additionally, pre-clinical studies demonstrate beta ()-adrenergic receptor 
activity is linked to HER2 expression.(96) Furthermore, trastuzumab triggers 
mitochondria oxidative stress and induces the expression and activation of pro-
apoptotic proteins. This causes mitochondrial damage, opening of the mitochondrial 
permeability transition pore, and induction of cell death pathways.(97) The incidence of 
symptomatic HF with Trastuzumab monotherapy is approximately 4% although can be 
as high as 27% with the concurrent use of ACTs.(45) The reduction in LV dysfunction is 
considered reversible with the cessation of therapy.(47)  
 
Endocrine Therapy 
 Tamoxifen use is associated with an overall beneficial effect on lipid profiles, 
however long-term clinical trials data have failed to show this translates into a CV 
benefit.(98) In fact, the risk of VTE  events, and stroke although rare has been shown to 
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be increased with the use of tamoxifen over placebo or AI.(99) Anastrozole, an AI with 
long-term safety data available has been associated with fewer thromboembolic and/or 
cerebrovascular events compared with Tamoxifen, but no significant difference in CV 
events.(100) 
 
Radiotherapy 
Radiation-induced heart disease (RIHD) is a heterogeneous clinical syndrome 
characterized by symptoms related to an impaired cardiac function (diastole and/or 
systole) related to radiation-injury to one or more cardiac structures (myocardium, 
pericardium, valves, coronary arteries). RIHD may present acutely during treatment in 
the form of acute radiation myocarditis, but more commonly develops over the long-term 
leading to leading to a restrictive cardiomyopathy.(101) Radiotherapy is associated with 
macrovascular, microvascular, endothelial dysfunction, valvular dysfunction, 
atherosclerosis, myocardial fibrosis, and pericardial disease.(102) 
The damage from RT causes cellular vasodilation, platelet aggregation, 
increased vascular permeability, and secretion of adhesion molecules and growth 
factors from injured endothelium prompting activation of the acute inflammatory 
response. Inflammatory cells secrete pro-fibrotic cytokines which convert fibroblasts to 
myofibroblasts that stimulate excessive extra-cellular matrix (ECM) formation, this 
accumulation of ECM leads to fibrosis.(103)  
In a population-based case-control study of incident HF in female breast CA 
patients who underwent contemporary RT, HF with preserved ejection fraction (HFpEF) 
defined as a LVEF ≥ 50% with HF symptoms was the most predominant HF 
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phenotype.(104) The relative risk of HFpEF increased with increasing mean cardiac 
radiation dose (MCRD), and risk of HF was higher in those with prior history of CVD or 
atrial arrhythmias.  
Late-onset RIHD occurs at a median of 10–15 years after exposure although the 
increased risk starts within the first 5 years and persists at least until the 3rd 
decade.(102, 105) The risk of RIHD is magnified by higher dose, delivery technique, 
younger age at the start of RT, longer duration since exposure, use of adjuvant 
chemotherapy, pre-existing CVD, and pre-existing CVD risk factors.(102) A large meta-
analysis involving 289,109 women revealed those who underwent RT for left (L)-sided 
vs. right (R)-sided breast CA had a higher risk of CV death and this was more apparent 
with prolonged follow-up (≥15 years).(106) 
Radiotherapy dose to the heart can vary considerably with mean doses of 1-2 Gy 
for R-breast disease, but as much as 10 Gy for treatment of the L-breast.(107) To 
account for this variability, a population-based case-control study of women with 
invasive breast CA who underwent external-beam RT was undertaken to determine the 
risk of CVD considering an individual patient’s RT dose and the presence of CVD risk 
factors present during treatment.(105) In women exposed to a range of 0.03 to 27.72 
Gy (MCRD = 4.9 Gy) using conventional or modern RT techniques the risk of major CV 
events increased linearly with MCRD to the heart. Cardiovascular disease risk 
increased 7.4% per Gy of mean heart dose with no discernible threshold dose below 
which CV risk did not exist.(105)  
The heart dose of RT in the CA patient has decreased over time with the use of 
modern RT techniques.(108) This includes the application of 3-dimensional CT 
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treatment planning for accurate heart dose and volume calculation, cardiac shielding, 
reduced heart dose per fraction (<2.0 Gy/day), reducing total heart dose (<30 Gy), 
breath-holding techniques, and the use of intensity-modulated RT.(109) 
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III. Methods to Detect Cardiotoxicity in the Patient with Cancer 
 
Methods to detect cardiotoxicity in the CA patient include multi-modality cardiac 
imaging to assess ventricular function, cardiac-specific biomarkers, and exercise testing 
while taking into account the patients’ intrinsic CV risk factor profile.(8) Chemotherapy-
related cardiac dysfunction (CTRCD) was first described in the late 1960’s based upon 
the presence of HF symptoms following the introduction of ACT for the treatment of 
CA.(110) The usefulness of LVEF by non-invasive cardiac imaging to detect 
cardiotoxicity was first reported in 1981 and initiated an era of using symptomology and 
assessment of LV function to monitor cardiotoxicity in the CA patient.(111) The 
evaluation of LVEF has emerged as the most widely used strategy for detecting 
changes in cardiac function during CA treatments. Resting LVEF, however, only 
provides a snap-shot of cardiac function, is dependent upon preload and HR, and is not 
prognostic in patients with preserved LVEF (>50%).(112) Impairments can also occur in 
diastolic relaxation and filling following CA therapy despite a preserved LVEF.(113)  
  
Radionuclide Imaging 
A multi-gated acquisition (MUGA) scan provides a cinematographic (cine) image 
of the beating heart by using a radioactive tracer that emits gamma rays that is injected 
into the blood with a gamma camera to detect the radiation released by the heart. It has 
historically been used to calculate the LVEF, define clinical cardiotoxicity, and risk 
stratify patients undergoing chemotherapy.(114) Guidelines for the use of MUGA to 
detect an asymptomatic decline in LVEF were developed to guide ACT treatment using 
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an LVEF decrease of ≥10% to indicate cardiotoxicity.(114) The advantages of MUGA 
for the assessment of LVEF are its high reproducibility, low variability, few technical 
limitations, and its widespread use in clinical practice.(115) It outperforms two-
dimensional echocardiography (2DE) with respect to accuracy and reproducibility of 
LVEF measurements.(116) The primary disadvantage of MUGA is incidental radiation 
exposure.(117) Furthermore, MUGA has significant variability in measurements of LV 
diastolic function, is non-informative on valvular or pericardial disease, and requires the 
use of supine bicycle exercise to measure LV functional reserve which is not readily 
available in standard clinical practice.(118) 
 
Echocardiography 
 Echocardiography (echo) is the cornerstone of cardiac imaging due to its 
widespread availability, safety, ease of repeatability, and lack of radiation exposure. It 
uses high-frequency ultrasound waves from a transducer to create images of the heart. 
In addition to its ability to determine cardiac dimensions, it also allows a comprehensive 
assessment of systolic and diastolic function at rest and with exercise, cardiac valves, 
the aorta, and the pericardium in the patient.(119) 
 The most commonly used parameter for estimating LV function with echo is the 
LVEF. The recommendations for chamber quantification from the American Society of 
Echocardiography and European Association of Echocardiography have established an 
LVEF ≥ 55% as normal with a reference range of 53 – 73% using the modified biplane 
Simpson’s technique with 2DE.(120, 121) Changes in loading conditions are frequent 
during chemotherapy and may affect the LVEF due to volume expansion with IV 
 
33 
 
 
 
administration or volume contraction due to vomiting or diarrhea. However, the 
incorporation of contrast, stress, three-dimensional, speckle-tracking, and tissue 
Doppler imaging echocardiography improve its clinical predictive value. 
 Although LVEF is a strong predictor of cardiac outcomes in the general 
population, 2DE often fails to detect small changes in LV systolic function.(122) A study 
by Thavendiranathan et al., concluded 2DE to be reliable in the detection of 10% 
differences in LVEF in CA patients undergoing chemo.(123) A drop in LVEF of 10% is 
highly significant and may be irreversible suggesting more sensitive parameters of LV 
function would be useful.(124) This lack of sensitivity has led to the increasing use of 
speckle-tracking echo and Doppler imaging to detect subtle changes in myocardial 
function.  
 Speckle tracking or strain-imaging utilizes the movement of the coherent 
ultrasound backscatter speckle pattern within echo images to assess myocardial strain 
throughout the cardiac cycle. The ventricular myocardium simultaneously shortens 
during systole in the longitudinal and circumferential planes and thickens in the radial 
plane, with reciprocal changes in diastole. Strain imaging allows for assessment of 
myocardial shortening and lengthening throughout the cardiac cycle by assessing 
regional myocardial strain and strain rate. Strain is defined as the change in length of a 
segment of myocardium relative to its resting length and is expressed as a %; strain 
rate is the rate of this deformation. Global longitudinal strain (GLS) is the preferred 
marker of myocardial deformation for the early detection of sub-clinical LV 
dysfunction.(125)  
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In 81 breast CA patients treated with chemo who were followed for 15-months 
with quarterly echo, the GLS after the completion of ACT predicted subsequent 
CTRCD.(126) Erven et al. demonstrated the ability of strain to detect deficits in breast 
CA patients undergoing RT wherein L-sided patients demonstrated strain and strain rate 
reductions after RT that was dose dependent with abnormalities in segments exposed 
to >3Gy.(127) 
 Diastolic dysfunction often precedes changes in systolic dysfunction in patients 
receiving anti-CA therapies.(128) An early reduction in the mitral annular early diastolic 
velocity (e’) has been repeatedly observed in patients receiving ACT chemotherapy and 
appears to predict future decline in systolic function.(113)   
 
Cardiac Magnetic Resonance Imaging  
 Cardiac magnetic resonance imaging (CMR) is very accurate for the calculation 
of LV mass, volumes, and LVEF(129) and when coupled with late-gadolinium contrast-
enhancement (LGE) is considered the gold-standard for the determination of myocardial 
tissue structure.(130) The use of CMR may identify a higher prevalence of myocardial 
injury/scarring in the CA patient and has higher intra- and inter-observer reproducibility 
compared with echocardiography.(131) It also allows characterization of myocardial 
edema, inflammation, and fibrosis thus permitting detection of early and late 
cardiotoxicity in the CA patient.(132) The benefit of CMR is that it is non-invasive, does 
not involve radiation, and demonstrates high-resolution through high contrast to noise 
ratios providing enhanced discrimination between endocardial and epicardial 
borders.(133) Disadvantages include lack of widespread availability, higher cost, and 
 
35 
 
 
 
contraindications involving ferromagnetic devices (i.e. pacemakers, defibrillators, breast 
tissue expanders) and claustrophobia.(125) 
 In CMR, the magnetic fields affect the hydrogen nuclei in the body, which act like 
miniature magnets. Gradients created by additional coils in the scanner cause a 
spatially related difference in how these hydrogen nuclei are affected. Generated 
radiofrequency (RF) pulses can then be used to manipulate the hydrogen nuclei in 
select planes of any predetermined location and size. Owing to their magnetic 
properties, the hydrogen nuclei that are affected by the RF pulse will give off an 
electromagnetic signal that can be detected, transformed, and displayed as a 2- or 3-
dimensional image. Gating of images by HR is achieved by ECG leads placed on the 
patient. Cine imaging provides moving images of the heart and surrounding structures.   
 
Cardiac-specific Biomarkers 
 Cardiotoxicity in the CA survivor defined by LVEF is not sensitive to detect late 
declines in heart function and the presence of a normal LVEF does not exclude the 
possibility of cardiac dysfunction.(48) Measurement of cardiac biomarkers can be a 
valid diagnostic tool for early diagnosis, assessment, and monitoring of cardiotoxicity. 
They can be easily repeated, are minimally invasive, allow early diagnosis, are relatively 
low cost, and do not predispose to incidental irradiation.(124) There may also be benefit 
from combining circulating biomarkers with the results of imaging modalities.(134)  
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Markers of Myocardial Injury – Cardiac-specific Troponins 
 Cardiac troponin (cTn) is the recommended biomarker for acute cardiac injury 
and elevations correlate with clinical severity, mortality, and cardiotoxicity from anti-CA 
therapies.(135) Cardiac troponin I (cTnI) and troponin T (cTnT) are the cardiac isoforms 
of regulatory proteins involved in muscle contraction thus when they are released into 
the circulation are highly specific for myocardial damage.(136) These two isoforms arise 
from the same circumstances (i.e. cardiac injury), but vary in concentration, and show 
differences in diagnostic accuracy.(137) Abnormally elevated levels of circulating cTn 
are found in HF patients without obvious myocardial ischemia or the absence of CAD 
suggesting ongoing cardiomyocyte injury or necrosis.(138) 
Studied most extensively in ACT-induced cardiotoxicity, cTn identifies patients at 
risk of future cardiotoxicity, have high negative predictive value to identify those at low 
risk of toxicity, and strongly correlate with changes in LVEF.(139, 140) In L-sided breast 
CA patients undergoing RT who were chemotherapy-naive, cTnT increased in a 
significant proportion of patients (21%) after RT, and correlated with whole heart dose 
and LV chamber dose.(141) Recently, highly sensitive cTn assays have been 
developed that can measure to an order of magnitude lower than previously 
possible.(142) This allows detection of some cTn level in most individuals likely due to 
cardiomyocyte turnover and may allow detection of subclinical cardiac dysfunction.(142)   
  
Markers of Left Ventricular Wall Stress - Natriuretic Peptides 
 Natriuretic peptides are secreted by the heart and produced in response to 
ventricular wall stress from pressure or volume overload.(143) The natriuretic peptides, 
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B-type natriuretic peptide (BNP) and its amino-terminal fragment precursor N-terminal 
pro-brain natriuretic peptide (NTproBNP) are recommended for the diagnosis and risk 
stratification of patients with HF although NTproBNP may be more useful to recognize 
early subclinical cardiac dysfunction.(144, 145) In the primary care setting involving 
patients without HF, NTproBNP levels can also discern between the presence of LV 
systolic dysfunction using a cut-off value of 125 picograms per milliliter (pg/mL).(146) It 
must be noted however that NTproBNP varies with age, gender, and renal 
function.(147) 
 In CA patients, natriuretic peptides generally correlate with increased risk of 
subsequent cardiotoxicity and elevated NTproBNP raises concern for elevated filling 
pressures, but professional organizations encourage further study on their utility before 
standard recommendations can be made.(125) However, it has been shown that 
NTproBNP levels are higher after RT for L-sided breast CA compared with non-RT 
matched controls and that NTproBNP correlates with heart volume and %volume of 
heart receiving higher doses.(148) It is noteworthy, in this same study cTnI levels did 
not  significantly change following RT and remained below the cut-off threshold. 
  
Emerging Novel Biomarkers 
 The American College of Cardiology Foundation/ American Heart Association 
guidelines for the management of HF give a Class IIb rating for the measurement of 
biomarkers of myocardial injury/stress or fibrosis and identify Galectin-3 for added risk 
stratification in the chronic HF patient.(145) Galectin-3, a β-galactoside–binding lectin 
member of the galectin family is also a marker of the inflammatory response in HF. Its 
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expression is increased in activated macrophages and is involved in pathological 
remodeling leading to fibroblast proliferation and collagen deposition.(149) 
C-reactive protein (CRP) is an acute phase reactant synthesized by hepatocytes 
in response to pro-inflammatory cytokines and is part of the innate immune 
response.(150) In addition to being a non-specific marker of an inflammatory process, 
CRP plays a key role in the inflammatory process of atherosclerosis.(151) High-
sensitivity C-reactive protein (hsCRP) allows detection of subclinical inflammation and is 
associated with worsening hemodynamics and outcomes in heart failure.(152) In the 
prediction of cardiotoxicity, work has shown correlations between hsCRP levels and 
later development of cardiomyopathy in patients treated with targeted therapies (i.e. 
Trastuzumab).(153) 
Together, these novel biomarkers with HF risk status properties and mechanisms 
similar to established anti-CA cardiotoxic mechanisms would seem to be viable 
candidates to quantify the incidence of late cardiotoxicity, but to date their utility is 
equivocal.(134) 
 
Stress testing  
 Stress testing can elicit CV and pulmonary abnormalities not present at rest and 
allows the quantification of functional reserve through the use of physical stress (i.e. 
exercise) or pharmacologic stress (i.e. sympathomimetic agents).(154) Exercise ECG 
testing has been used for over 60 years to provoke and identify myocardial ischemia, 
but over the last several decades been increasingly applied to assess CV risk.(155) 
When coupled with imaging modalities such as echo or perfusion studies it can provide 
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even greater diagnostic accuracy.(154) Exercise capacity and assessment of cardiac 
contractile reserve are independent predictors beyond coronary anatomy and 
LVEF.(156, 157) The potential role of exercise capacity to diagnose CA-related toxicity 
is discussed in section IV of this review. 
In a study comparing the incidence and distribution of CAD after L-sided versus 
R-sided RT following BCS for early-stage breast CA (12-years post-RT), the L-sided 
group demonstrated a significantly higher prevalence of stress abnormalities (59% vs. 
8%) using stress echo or perfusion studies.(158) Furthermore, the L-sided abnormalities 
were predominantly (70%) in the L-anterior descending artery region illuminating the 
importance of RT techniques.(158)  
Stress echocardiography has shown usefulness in the detection and prognosis of 
stable CAD in patients with an intermediate or high pre-test probability for CAD who 
underwent chemotherapy regimens associated with ischemia (i.e. 5-FU).(159) Kearney 
et al. demonstrated the utility of stress echo using strain to detect subclinical LV 
dysfunction in long-term (36 10 years) CA survivors following prior ACT exposure 
(118 years post-treatment).(160) Similarly, Khouri et al. showed the superiority of 
exercise 2DE to detect subclinical cardiotoxicity not apparent with resting 2DE in breast 
CA patients undergoing adjuvant therapy.(161) 
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IV. Cardiorespiratory Fitness in Breast Cancer Patients Who Have 
Undergone Anti-Cancer Treatments. 
 
Cardiorespiratory fitness (CRF) is a strong and independent predictor of both all-
cause and CVD-related mortality wherein high-levels confer protection.(162, 163) 
Furthermore, it is a predictor of breast CA-specific mortality as well as the risk of a 
breast CA diagnosis.(164, 165) Finally, it appears to be reduced in breast CA 
survivors.(166)  
Cardiorespiratory fitness is defined as the ability of the circulatory, respiratory, 
vascular, and muscular systems to supply oxygen (O2) during sustained physical 
activity. It is typically expressed as maximal oxygen uptake (VO2 max) obtained during 
progressive maximal dynamic exercise. Maximal VO2 implies the observance of a 
plateau in O2 uptake values which is rarely observed in clinical practice thus the term 
peak VO2 is often used as a surrogate.(167)  
Cytotoxic anti-CA therapies are associated with fatigue, exercise intolerance, 
cardiomyopathies, and skeletal muscle myopathies that can occur with active treatment 
and persist in the post-treatment period.(168) This can be due to pain, emotional 
distress, anemia, weight gain, sedentarism, sleep disturbances, nutritional deficits, 
decreased functional status, medication side-effects, and comorbidities.(169)  
An analysis by Peel et al. developed normative values for peak VO2 in breast CA 
patients.(170) They identified 27 clinical trials involving a total of 1,856 females (mean 
age=52 years) directly measuring peak VO2 in the pre- or post-adjuvant setting. 
Adjuvant therapy included chemotherapy in 78% (mostly ACT), RT in 56%, and ET in 
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33% of patients. The mean peak VO2 prior to adjuvant therapy was 24.6 ml•kg-1•min-1, 
whereas the mean peak VO2 post-adjuvant therapy was 22.2 ml•kg-1•min-1. This 
equates to a post-adjuvant reduction in VO2 of -2.4 ml•kg-1•min-1or 10% lower.  This was 
accompanied by a mean post-adjuvant BMI increase of 2.6 kg/m2.  Linear meta-
regression analysis of BMI and age with peak VO2 did not provide evidence of an 
association (P>0.05). Compared with reference values the pre-adjuvant VO2 values 
were significantly lower (17%) than that of healthy, sedentary women (29.7 ml•kg-1•min-
1) or 83% of predicted (%pred.) (P=0.007). In the post-adjuvant setting, pVO2 was 25% 
lower (75%pred.) (P<0.001) compared to healthy, sedentary values. For comparison, 
the mean VO2 of a typical 50-year-old breast CA patient (22.6 ml•kg-1•min-1) was similar 
to the VO2 of a healthy 60-year-old sedentary woman (~22.7 ml•kg-1•min-1). 
Jones et al. evaluated VO2 across the entire breast CA treatment continuum and 
assessed its significance in metastatic disease.(171) A total of 248 women (mean age 
of 55±8 years) underwent CPET. Patients were divided into four cross-sectional 
treatment cohorts: 1) pre-adjuvant (n=20), 2) during adjuvant (n=46), 3) post-adjuvant 
(mean time=27 months, n=130), 4) during adjuvant-therapy with metastatic disease 
(n=52). In the post-adjuvant cohort, RT was part of treatment in 102 (78%) patients. The 
mean peak VO2 was 17.8±4.3 ml•kg-1•min-1 (73% pred.). As expected there was a 
significant difference between peak VO2 values observed between the different cohorts 
with the metastatic disease cohort displaying the lowest peak VO2 values (16.3±3.5 
ml•kg-1•min-1). In the metastatic cohort, peak VO2 in absolute values (L•min-1) held 
prognostic utility when comparing those <1.09 L•min-1 wherein the adjusted hazard ratio 
for death was 0.32 (95%CI, 0.16-0.67; P=0.002) for a peak VO2 >1.09 L•min-1. 
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Germane to this review, individuals in the post-adjuvant setting had a mean VO2 of 
18.4±4.1 ml•kg-1•min-1 (78% pred.). This was in the setting of a normal LVEF (62%), 
normal peak HR (96% pred. max HR), and normal hemoglobin levels (13.5 g/dL). 
 
1) Central Factors associated with CRF 
Maximal VO2 is considered the metric that defines the limits of the 
cardiopulmonary system. It is defined by the Fick equation as the product of cardiac 
output (CO) and arteriovenous oxygen content difference (a-vO2 diff). Cardiac output 
(HR x stroke volume (SV)) is regarded as the primary determinant of CRF(172) thus any 
sequelae of anti-CA treatment that impacts chronicity, contractility, preload, or afterload 
could adversely affect CO and ultimately CRF.  
When considering that the primary analysis of cardiotoxicity in patients receiving 
anti-CA therapies revolves around the measurement of LV systolic function to diagnose 
HF, it is important to recognize more than half of HF patients have HFpEF.(173) Breast 
CA survivors also share a number of HFpEF risk factors (female, older age, HTN, 
obesity, sedentary lifestyle).(174)  
Khouri et al. assessed CRF, as well as CO (using 2DE) at rest and immediate 
post-exercise in 57 women with early-stage breast CA (age=51 years; time post-
chemotherapy=26 months; LVEF=55%) and sex-matched healthy controls. Peak VO2 
was 20% lower in the breast CA cohort with no significant difference between groups for 
maximal HR. Post-exercise SV and cardiac index were significantly lower although post-
exercise left-ventricular end-diastolic volume (LVEDV), LVEF, and LVEF reserve were 
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not significantly different between groups. Cardiac index reserve was significantly 
related to peak VO2.(161)  
Koelwyn et al. evaluated LV volumes and ventricular-arterial coupling and 
VO2 during cycle exercise, using 2DE, in 30 older BC patients (age= 61 years; time 
post-chemotherapy= 6.5±3.6 years, 77% underwent RT; LVEF=60%) and 30 age-
matched controls. Peak VO2, sub-maximal exercise LVEDV, SV, and effective arterial 
elastance were not different between groups. However, sub-maximal exercise LVEF 
was significantly lower secondary to decreased end-systolic elastance (an indirect 
measure of LV contractility).(175) These studies insinuate a CV limitation in CRF 
despite a normal LVEF. 
 
2) Peripheral Factors associated with CRF 
The benefit of CRF assessment is that it provides a global assessment of the 
components that transport O2 from the atmosphere into the mitochondria termed the O2 
cascade. Any therapy that affects components of the Fick equation (CO or a-vO2 diff) 
will reduce CRF. Although CO is considered the primary determinant of CRF, anti-CA 
therapies are known to cause vasculature injury, pulmonary dysfunction, anemia, and 
skeletal muscle dysfunction.(66)  
Beckman et al. evaluated the effect of RT on endothelium-dependent 
vasodilation in 16 breast CA patients (>3 years post-RT) compared with healthy 
controls. Using vascular ultrasonography and flow-mediated (FMD) endothelium-
dependent (FMED) and endothelium-independent vasodilation (FMEI) techniques, 
FMED vasodilation was significantly impaired in the irradiated axillary arteries compared 
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with the contralateral, non-irradiated arteries and also compared with healthy control 
arteries. Conversely, the FMEI vasodilation was greater in the irradiated arteries 
compared with the contra-lateral arteries and controls.(176)  
Conversely, Jones et al. examined brachial artery FMD in 26 HER2+ breast CA 
patients (age=48 years; time post-chemo=20 months; 65% underwent RT, LVEF=64%) 
and 10 healthy controls. The brachial artery FMD  (FMED and FMEI) was not 
significantly different between groups (all P>0.1), and not related to peak VO2 (P>0.5) 
although pVO2 was significantly inversely related to BNP (R=-0.53,P=0.006).(174) 
Koelwyn et al. extended these findings by demonstrating that brachial artery FMD, 
carotid-femoral and carotid-radial pulse wave velocity, and carotid compliance were not 
significantly different between breast CA and healthy controls.(175) This suggests large 
conduit artery endothelial function and arterial stiffness are not impaired in breast CA 
patients. 
Reactive oxygen species, mitochondrial dysfunction, and inflammatory processes 
have been purported in the literature to be involved in chemotherapy-induced skeletal 
muscle dysfunction.(177) In an animal model, with adult mice injected with a single dose 
of cyclophosphamide, treadmill running time was decreased and mitochondrial function 
(maximal ATP production, phosphocreatine to ATP ratio) remained persistently below 
baseline following exposure at 6 weeks.(178) 
Decreased CRF may also be the result of peripheral muscle weakness as peak 
VO2 is related to leg strength in older BC patients.(179) A majority of the O2 consumed 
during exercise occurs in the active skeletal muscle thus a decline in peak VO2 in CA 
may be due to a reduction in the quantity or quality of skeletal muscle. Villasenor et al. 
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showed that sarcopenia is prevalent and an independent predictor of prognosis in older 
breast CA.(180) Finally, Toth et al. demonstrated that before or during CA treatment in 
19 CA patients (6=breast), muscle fiber cross-sectional area for both slow-twitch myosin 
heavy chain (MHC) I and fast-twitch MHC IIA was reduced (~20%) and correlated with 
functional capacity.(181)  
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V. Cardiopulmonary Exercise Testing in Cancer Patients Who Have 
Undergone Anti-Cancer Treatments. 
 
  Cardiopulmonary exercise testing is most extensively used in the CA literature to 
determine eligibility for surgery and post-operative prognosis as it applies to lung CA 
surgery.(182) Specific to clinical oncology, in 2008 Jones et al. performed a systematic 
review of formal CPET for adults with CA.(183) Using the recommendations for CPET 
from the American Thoracic Society/American College of Chest Physicians they 
attempted to quantify the quality of CPET results in the literature performed on adult CA 
patients. Their results suggest the reporting of CPET methods and data do not comply 
with national and international quality standards and they provide recommendations to 
improve consistency of data reporting and methodology for exercise-oncology 
researchers and clinicians caring for the adult oncology patient.   
 Using relevant terms, they identified 90 citations that met inclusion criteria.  
These 90 studies included 5,179 adults and were dichotomized into two groups: 1) 
performed CPET solely for quantification of CRF and 2) CPET performed as part of an 
intervention study.  By and large, most tests were performed on women and assessed 
patients with breast or lung CA either during or after treatment. 
Peak VO2 was the most commonly reported exercise variable. In regards to effort 
performance, 28/90 (31%) reported peak HR and only 11/90 (12%) reported the peak 
respiratory exchange ratio. This has major implications if one is trying to determine the 
robustness of peak exercise variables or assess the efficacy of an intervention. 
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 In regards to assessment of the exercise response, 6/90 (7%) reported the 
ventilatory threshold, 3/90 (3%) reported the peak O2 pulse, 11/90 (12%) reported 
symptoms for test termination, and only 14/90 (16%) reported some metric of 
ventilation.  These variables provide both prognostic and pertinent information to detect 
the physiologic or possibly pathophysiologic limitations to exercise.(167) Furthermore, 
they may be sensitive to change resulting from a therapeutic intervention.(184) 
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Conclusions 
 
In conclusion, CA-associated cardiotoxicity is an important concern in the 
growing population of survivors mostly consisting of breast CA patients. Multi-modality 
treatments are improving outcomes yet this may come at the expense of increased late 
CV risk. Current CV detection methods are based mostly on resting measures of LV 
systolic function. There is a need to expand this cardio-detection armamentarium to 
include measures of functional reserve such as CRF. The literature to date, although 
limited, indicates significantly reduced CRF following anti-CA therapies. The data is 
stronger for the adverse effects of anti-CA chemotherapeutic regimens, whereas the 
effects of RT with heart involvement, a recognized risk factor for CVD, on CRF has not 
been systematically examined. Incorporation of CPET into the assessment of patients 
who have received radiation to the chest may help understand the short- and long-term 
consequences and enhance detection of toxicity related to this form of anti-CA therapy. 
Enhanced detection will likely improve the quality of clinical care and provide insight to 
the mechanisms contributing to morbidity/mortality in the chest CA patient.  
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Chapter 2: Impaired Cardiorespiratory Fitness Following Thoracic Radiotherapy 
 
 
 
ABSTRACT 
Introduction: The risk of cardiotoxicity is one of the most detrimental adverse reactions 
of radiotherapy (RT) and leads to a significantly increased risk of cardiovascular disease 
(CVD) mortality and morbidity. RT induces a cardiomyopathy in a dose-dependent 
manner that leads to impairment in cardiac diastolic and systolic function. Clinical 
presentation of cardiotoxicity after RT is often delayed several years where the cardiac 
reserve is severely impaired and patients show signs of heart failure. In animal models 
the injury to the heart, however, starts immediately during RT where subtle structural 
and functional changes in the heart are evident early after RT. In the current study we 
sought to determine whether patients who had received RT to the chest demonstrated 
exercise intolerance, a marker of impaired cardiac reserve, due to impaired cardiac 
function.  
Methods: We enrolled 30 patients 2.0 (0.6-3.8) years after completion of RT to the 
chest for the treatment of cancer (CA) with the radiation field involving at least 10% of 
heart volume receiving at least 5 Gray (Gy) of radiation. Patients underwent 
cardiopulmonary exercise testing, stress echocardiography, cardiac magnetic 
resonance imaging, and biomarkers assessment. Exercise intolerance was defined as a 
reduction of peak oxygen consumption (VO2) <83% of predicted.  
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Results: The overall cohort was predominantly Caucasian (n=20 [67%]), mostly female 
(n=18 [60%]) with a median age of 63 (57-67) years. The peak VO2 was 16.9 (14.4-
20.8) mL·kg-1·min-1 or 62% (52-89%) of predicted, reflecting a peak VO2 <90% predicted 
in >75% of cases. The mean cardiac radiation dose for the entire cohort was 5.6 (3.7-
17.8) Gy and demonstrated a significant inverse association with peak VO2 (R=-0.380, 
P=0.04). Multivariate regression revealed the diastolic functional reserve index (DFRI) 
measured as the velocity of the mitral annulus at tissue Doppler (e’) at rest multiplied by 
the change in e’ with exercise (e′rest•Δe′exercise - ß=0.765, P<0.01) and N-terminal pro-
brain natriuretic peptide (NTproBNP) serum levels (ß =-0.389, P=0.04) were both 
independent predictors of peak VO2. 
Conclusions: Patients with CA who received radiation therapy to the chest involving 
the heart show a dose-dependent impairment in cardiorespiratory fitness (peak VO2) 
associated with a reduced cardiac diastolic reserve (DFRI) and markers of myocardial 
strain due to elevated filling pressures (NTproBNP levels). 
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INTRODUCTION 
Cancer (CA) is the second leading cause of death in the United States (U.S.) 
preceded only by cardiovascular disease (CVD).(1) Over the past 30 years, the 5-year 
survival rate for all cancers combined has increased by more than 20% at similar rates 
between both sexes.(185) This improved survival rate is due to early diagnosis and 
advances in treatment involving a multimodality treatment approach that involves 
surgery, systemic therapy, and radiotherapy [RT] with about half of all CA patients 
receiving some type of RT sometime during the course of their treatment.(4, 185) 
Cardiotoxicity, a general term used to describe "toxicity that affects the heart", is 
one of the most important adverse reactions of RT and leads to a meaningful risk of 
CVD-related morbidity and mortality.(6, 7) The improvement in survival rate means 
there are a greater number of CA patients living with the potential adverse effects of 
these anti-CA therapies such as RT. Cardiotoxicity related to RT is important to 
recognize as it may have a significant impact on the overall prognosis and survival of 
CA patients where the CA-related benefits of RT may be offset by an increased risk of 
CVD events. 
Radiotherapy-related cardiotoxicity is a heterogeneous clinical syndrome 
characterized by symptoms related to impaired cardiac function due to radiation-injury 
to one or more cardiac structures. Radiotherapy-related cardiotoxicity may present 
acutely during treatment in the form of acute radiation myocarditis, which is rare, and 
more commonly develops over the long-term leading to a restrictive-type of 
cardiomyopathy.(101)  
In a population-based case-control study of incident heart failure (HF) in female 
breast CA patients (the most common CA subtype) who underwent contemporary RT, 
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HF with preserved ejection fraction (HFpEF) defined as a left-ventricular ejection 
fraction (LVEF) ≥ 50% with HF symptoms was the most predominant HF 
phenotype.(104) Furthermore, the relative risk of HFpEF increases with increasing 
mean cardiac radiation dose (MCRD).(104) 
There is not a unified consensus on the definition of CA-related cardiotoxicity 
although most trials have focused on changes in resting systolic function, namely LVEF 
and/or development of HF symptoms.(61, 62) Commonly used tools to assess cardiac 
function (i.e. LVEF) are notoriously insensitive to minor injury, and hence subtle 
changes may go unnoticed for many years.(122) When considering that cardiotoxicity 
revolves around the measurement of LV systolic function to diagnose HF, it is important 
to recognize more than half of all HF patients have HFpEF.(173) Based on the 
prevalence of HFpEF, a greater need for dynamic functional assessment of the CV 
system in addition to measures of resting myocardial function may be warranted in 
defining cardiotoxicity. This may allow detection of latent CV abnormalities before the 
precipitous decline of resting myocardial function or the development of CV 
symptomology that may impact quality of life.(64)  
Cardiopulmonary exercise testing (CPET) including measurement of peak 
oxygen consumption (VO2) is considered the gold standard for the assessment of 
cardiorespiratory fitness (CRF).(186) Cardiorespiratory fitness is a strong, independent 
predictor of mortality, CVD-related mortality, HF-related morbidity and mortality, CA-
related mortality and may be involved in the pathophysiologic link between anti-CA 
related treatments and the increased risk of late CVD morbidity and/or mortality.(66, 
163, 164, 187) Emerging evidence indicates CRF may be reduced in CA survivors.(170)  
 
53 
 
 
 
To date, no one has examined the contribution of contemporary RT on CRF in 
patients with CA. Moreover, the degree of reduction in CRF, the primary limitation (i.e. 
heart vs. lungs), the determination of a dose-response (MCRD-∆VO2) relationship, and 
the mechanistic link attributable to specific anti-CA therapies such as RT are all 
unexplored. 
The purpose of this pilot project was to evaluate CRF with an emphasis on peak 
VO2 and its determinants in a subset of CA patients who had previously undergone RT 
involving a significant dose to the heart. The hypothesis of this study is that patients with 
CA who have previously undergone RT with radiation dose to the heart have impaired 
cardiorespiratory fitness, measured as a reduction in peak oxygen consumption (VO2), 
mainly due to abnormal cardiac function, in a dose-dependent manner. The ability to 
demonstrate a significant relationship between exercise capacity, cardiac dysfunction, 
and RT regimen may signal the importance of CRF assessment in establishing latent 
cardiotoxicity.  
   
  
 
54 
 
 
 
METHODS 
 
We designed a single-center pilot prospective study in patients who had 
previously undergone irradiation to the chest including a clinically-significant radiation 
dose to the heart to obtain a cross-sectional assessment of RT cardiotoxicity.  
Potential subjects were identified during their routine clinical visits within the 
radiation oncology department at Virginia Commonwealth University (VCU) Medical 
Center according to the following inclusion and exclusion criteria:  
  
Inclusion criteria: 
• Previous thoracic radiotherapy to the chest;  
• minimum radiation dose to the heart of at least 5 Gray (Gy) involving at least 10 
percent (%) of the heart volume  
 
Exclusion criteria: 
• Inability to provide informed consent; 
• age <18 years; 
• contraindication to magnetic resonance imaging (MRI) with gadolinium contrast use 
(including, but not limited to implantable cardioverter defibrillator or pacemaker [not 
compatible with MRI] or moderate to severe renal impairment [glomerular filtration 
rate <60 mL/min/1.73 m2]); 
• pregnancy or breastfeeding; 
• inability to perform treadmill exercise testing; 
• prior history of significant cardiac disease (including prior myocardial infarction, HF, 
myocarditis, pericarditis, left ventricular hypertrophy, cardiomyopathy, pericardial 
effusion). 
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This study was approved by the VCU institutional review board (HM#20006724) 
prior to commencement and all subjects underwent informed consent prior to study 
procedures. Clinical data was extracted from the patient medical record. Cancer staging 
was based upon the American Joint Committee on Cancer (AJCC) Cancer Staging 
Manual 7th edition.(188) Cancers are staged (0–IV) with higher stages indicating larger 
tumors or the extent of spread to lymph nodes or other organs. 
Radiation dose calculation was performed based on a volumetric computed 
tomography (CT) data set obtained during a treatment planning session. A single well-
experienced radiation oncologist performed quantification of total radiation dose and 
volume of heart and lung exposed. Using dedicated treatment planning software 
(Pinnacle, Koninklijke Philips N.V.), the heart and lungs were manually contoured on 
each CT slice generating 3D structures. After radiation beam definition and target dose 
calculation, heart and lung dose was determined as maximum, minimum and mean 
dose (MCRD, MLRD) to the whole organ volume as well as using dose-volume 
histograms to generate %volumes of the heart receiving at least 5 Gy, 10 Gy, 20 Gy, 30 
Gy, 40 Gy, and 50 Gy, respectively (Figure 1).  
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Figure 1.  Example of a Dose-Volume Histogram to determine heart exposure during 
radiotherapy treatment. 
Abbreviations: Gy=Gray units; cGy= centigray. 
  
%Heart volume 
receiving at 
least 5 Gy 
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Patients were evaluated for signs of cardiotoxicity through the use of the 
following procedures:  
• Cardiopulmonary exercise testing (CPET) 
• Transthoracic Doppler echocardiography at rest and with exercise  
• Cardiac-specific blood-based biomarker analysis 
• Cardiac magnetic resonance (CMR) imaging with delayed-gadolinium enhancement 
(LGE).  
Additionally, all subjects underwent assessment of anthropometrics, physical activity 
participation, and completed a health-related quality of life (HRQOL) questionnaire to 
further characterize the cohort. 
 
Cardiopulmonary Exercise Testing 
A physician supervised, symptom-limited CPET was administered to all subjects 
by a clinical exercise physiologist using a conservative incremental ramping treadmill 
protocol wherein the speed and grade increased by approximately 0.3 estimated 
metabolic equivalents every 30 seconds.(189) Ventilatory gas-analysis was performed 
pre-, during, and post-exercise using a metabolic cart (Parvomedics, Sandy, UT) to 
measure ventilation (VE), VO2, and carbon dioxide production (VCO2). Prior to each test, 
the O2 and CO2 sensors of the metabolic cart were calibrated using gases of known O2, 
nitrogen, and CO2 concentrations and the flow sensor was calibrated using a standard 
3-Liter syringe.  
Contraindications to testing and test termination criteria were based upon 
established American Heart Association/American College of Cardiology guidelines for 
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exercise testing.(154) All subjects were instructed to follow standard pre-exercise test 
procedures as outlined by the American Thoracic Society/American College of Chest 
Physicians and evaluated by a physician prior to testing.(186) This included instructions 
to arrive in a fasting state, abstain from smoking at least 8 hours before testing, 
continuation of current medications, no exercise the day of testing, and to wear 
appropriate exercise attire. Subjects were briefed regarding the exercise protocol and 
encouraged to exercise to volitional fatigue. Twelve-lead ECG monitoring was 
conducted at baseline, throughout the test, and at least 5-minutes into the recovery 
period to assess heart rate (HR) and rhythm. Presence of exercise-induced 
atrial/ventricular arrhythmias (atrial fibrillation, ventricular ectopy ≥6/minute) and/or ST-T 
wave segment changes (≥1-mm horizontal or downsloping depression) indicative of 
myocardial ischemia were considered abnormal consistent with international 
guidelines.(154) Peak HR in beats per minute (bpm) was indexed to the age-predicted 
maximal HR to give a percentage using the commonly used equation: 220-age.(190) 
Chronotropic response to exercise was determined from the chronotropic index (CI), 
which is the difference between the peak HR and the resting HR relative to the 
metabolic requirement of exercise (peak VO2 minus resting VO2). A CI <0.80 without 
beta-blockade and ≤0.62 with beta-blockade was considered indicative of chronotropic 
incompetence and considered an abnormal response.(191, 192) Blood pressure was 
measured at rest, every two minutes during exercise, and into recovery using an 
automated exercise-compatible sphygmomanometer (Tango+, SunTech Medical, 
Morrisville, NC).  
 
59 
 
 
 
During CPET, VE was determined using a pneumotachometer, and expired 
gases were sampled to continuously measure VO2 and VCO2. The average value for 
VO2 during the last 30 seconds of exercise was used to define peak VO2 expressed in 
both absolute values (mL·min-1) and relative to bodyweight (mL·kg-1·min-1). Percent of 
predicted normal peak VO2 was calculated according to the prediction equations of 
Wasserman and colleagues.(193) The peak respiratory (VCO2/VO2) exchange ratio 
(RER) coinciding with the peak VO2 was used to quantify subject effort. Typically, an 
RER ≥1.1 is regarded as criterion of an excellent maximal cardiopulmonary effort.(194) 
However, in the clinical setting an RER ≥1.1 is often not attained although the 
prognostic utility of peak VO2 is retained leading to the acceptance of lower thresholds 
of >1.05 as good or ≥1.0 as acceptable effort.(167, 195–197) A RER<1.0 was used to 
reflect submaximal effort and/or a non-cardiac reason for stopping in the absence of any 
hemodynamic or electrocardiographic abnormalities.(154) A peak VO2 <83% of 
predicted values was used to identify an abnormal aerobic exercise capacity or exercise 
intolerance.(193)  
The peak oxygen pulse (O2 pulse) was defined as the ratio between peak VO2 
(mLO2·min-1) and peak HR in units of mL/beat. Percent predicted O2 pulse was defined 
as the percentage of the predicted value achieved by dividing the predicted peak VO2 
by age-predicted peak HR. An O2 pulse ≤85% of predicted was considered abnormal 
based on the findings of Oliviera and colleagues.(198) 
The ventilatory anaerobic threshold (VAT) was calculated using the dual-
methods criteria wherein the V-slope and the ventilatory equivalents methods were 
employed.(199) The V-slope method was graphically determined by departure of the 
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VO2 from a line of identity drawn through a plot of VCO2 versus VO2. The ventilatory 
equivalents method was determined from graphical and averaged tabular data as the 
point wherein a systematic increase in the ventilatory equivalent for oxygen (VE/VO2) 
occurs without an increase in the ventilatory equivalent for carbon dioxide 
(VE/VCO2).(186) A VAT less than the lower 95% confidence limits for the ratio of 
predicted VAT to predicted peak VO2 indicated abnormality.(193) 
Ten second averaged VE and VCO2 data, from the initiation of exercise to peak, 
were inserted into spreadsheet software (Microsoft Excel, Microsoft Corp., Bellevue, 
WA) to calculate the minute ventilation/carbon dioxide production (VE/VCO2) slope via 
least squares linear regression. Additionally, the VE/VCO2 slope was indexed to the 
peak VO2 to normalize ventilatory efficiency to exercise capacity.(200) The oxygen 
uptake efficiency slope (OUES) was determined from the linear relation of V̇O2 versus 
the logarithmic transformation of VE during exercise, i.e., V̇O2 = a log10 VE + b, where 
‘a’ is the OUES and ‘b’ is the intercept.(201) The %-predicted OUES was calculated by 
comparing the observed with the reference values put forth by Sun et al.(202) A %-
predicted OUES of <89% of predicted was considered indicative of an abnormal CV 
limitation as proposed by Barron et al.(203) The oxygen uptake efficiency plateau 
(OUEP) was calculated as the 90-second average of the highest consecutive 
measurements of VO2 (mL·min-1)/VE (L·min-1) during the exercise period.(202) 
A normal CV limitation to exercise was defined as a peak VO2 ≥83% of predicted 
values in the setting of an RER ≥1.0 with a peak HR ≥85% of age-predicted maximal 
HR.(167, 193, 204) A priori an abnormal cardiovascular response to exercise was 
defined as exercise intolerance (peak VO2 <83%) in the presence of any one of the 
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following observances in the absence of a pulmonary limitation to exercise and a peak 
RER ≥1.0: 1) VAT <95% confidence limits for the ratio of predicted VAT to predicted 
peak VO2(193); 2) Chronotropic index (CI) <0.80 or ≤0.62 with beta-blockade(191, 192); 
3) OUES <89% of predicted(203); 4) Peak O2 pulse <85% of predicted.(198)  This 
would indicate subclinical cardiac dysfunction related directly to undergoing RT 
treatment and provide a means for early detection of latent heart disease. Inability to 
detect an abnormal cardiac limitation to exercise posits that cardiovascular dysfunction 
is not what’s driving the exercise intolerance rather it is due to pulmonary limitations, 
deconditioning or excess body habitus, or that CPET variables may be insensitive to 
detect early cardiovascular dysfunction. A peripheral limitation to exercise was defined 
as a peak VO2 <83% with an RER <1.0 in the absence of any cardiovascular or 
pulmonary abnormalities. 
 
Pulmonary Function Testing 
All subjects underwent standard spirometry prior to exercise including 
performance of forced vital capacity (FVC), forced expiratory volume in one second 
(FEV1), the mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%), 
peak expiratory flow (PEF), and the directly-measured maximal voluntary ventilation 
(MVV) maneuver according to American Thoracic Society standards.(205) The 
presence and severity of airflow limitation was assessed according to Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) guidelines.(206) Peak exercise VE was 
compared to the MVV to assess ventilatory reserve with a peak VE/MVV ratio of >0.80 
indicating a pulmonary limitation to exercise.(207) Similarly, forehead pulse oximetry 
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was employed throughout exercise to estimate arterial hemoglobin oxygen saturation. 
Oxygen saturation values <95% at rest or >5% decrease with exercise were considered 
abnormal and indicative of a pulmonary limitation to exercise.(207) 
 
Doppler Echocardiography 
Standard two-dimensional transthoracic echocardiography was performed to 
measure left and right ventricular and atrial dimensions, left and right ventricular systolic 
function, stroke volume (SV), left-ventricular ejection fraction (LVEF), transmitral flow 
velocities [Early (E), Late (A), E/A ratio, and E wave deceleration time (DT)], tissue 
Doppler‐derived early diastolic mitral annular velocity (e′), and longitudinal systolic strain 
(s′) measured at tissue Doppler averaged between lateral and septal according to the 
recommendations of the American Society of Echocardiography.(120, 208, 209) All 
echocardiographic measurements and analysis were performed by trained cardiologists.  
Doppler derived cardiac output (CO) was estimated by measuring flow across the 
left ventricular outflow tract (LVOT) which is determined by the velocity time integral (VTI) 
of the Doppler signal directed across the LVOT (LVOT VTI) multiplied by the HR.(210) 
The LVOT VTI is used to estimate SV since it reflects the column of blood which moves 
through the LVOT during systole, per the following equation: SV = LVOT VTI x Cross 
Sectional Area (CSA) of the LVOT.(210) Since estimation of the CSA of the LVOT 
represents a potential source of significant error the LVOT VTI alone has been suggested 
as a reasonable surrogate for CO measurement.(211)  
The E/e’ ratio was calculated as an estimate of LV filling pressures.(212) The e′ 
velocity was indexed by the DT to obtain a measure (e′/DT) that reflected both the delay 
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in relaxation (DT) and the peak velocity in diastolic filling (e′).(213) A higher e′ and shorter 
DT would reflect better myocardial relaxation, whereas reduced e′ or prolonged DT would 
each reflect impaired relaxation with an additive value.  
Stress echocardiography was also performed to assess the LVOT VTI-derived CO 
(VTICO), E, lateral e′ and E/e′ ratio at peak exercise by having the patient sit down 
immediately post-exercise and obtaining an apical view in < 1-minute. The interval 
changes in VTICO, e′ and E/e′ were calculated (ΔVTICOexercise, Δe′exercise, ΔE/e′exercise), 
respectively. The diastolic functional reserve index (DFRI) was defined as the product of 
e′rest•Δe′exercise.(214) 
 
Cardiac-specific Blood-based Biomarker Assessment 
A blood sample was obtained prior to any study procedures and before exercise 
to measure the following biomarkers: 1) high-sensitivity cardiac troponin I (hs-cTnI); 2) 
high-sensitivity cardiac troponin T (hs-cTnT); 3) N-terminal pro-brain natriuretic peptides 
(NTproBNP); 4) galectin-3 (Gal-3); 5) high-sensitivity C-reactive protein (hsCRP). The hs-
cTnI and hs-cTnT plasma samples were collected in K2-Ethylenediaminetetraacetic acid 
(EDTA) tubes (Becton, Dickinson and Co., Franklin Lakes, NJ), centrifuged, frozen and 
shipped to Hamilton Health Sciences Research Laboratory (Hamilton, ON). The 
NTproBNP, Gal-3, and hsCRP plasma samples were collected in K2-EDTA tubes, 
centrifuged, and sent to a local laboratory (True Health Diagnostics, Richmond, VA).    
The hs-cTnI was determined using the Abbott ARCHITECT (Abbott Laboratories, 
Abbott Park, IL) high-sensitivity troponin I immunoassay. The Abbott hs-cTnI assay is a 
chemiluminescent microparticle immunoassay for the quantitative determination of the 
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cTnI in human plasma and serum. The Abbott hs-cTnI assay reportable range is 1 – 
50,000 nanograms per liter (ng/L) with a lower reportable limit of <1 ng/L.(142) The 99th 
percentile limit of the distribution of values in a reference population for males = 14.0 ng/L 
females = 11.1 ng/L, all-subjects = 13.6 ng/L, and at these concentrations the assay 
coefficient of variation (CV) is 5.0%.(142) 
The hs-cTnT was determined using the Roche Elecsys Troponin T Gen 5 STAT 
(Roche Diagnostics, Indianapolis, IN) electrochemiluminescence immunoassay with an 
analytical range from 3 to 10,000 ng/L. The 99th percentile limit of the distribution of values 
in a reference U.S. population is 19 ng/L for both genders, 14 ng/L for females and 22 
ng/L for males with a CV of <4%.(215)  
The NTproBNP was determined using the Roche Elecsys proBNP (Roche 
Diagnostics, Indianapolis, IN) immunoassay for the in vitro quantitative determination of 
N‐terminal pro‐brain natriuretic peptide in human serum and plasma. It has a measuring 
range of 5.00-35,000 pg/mL with a limit of detection (LOD) of <5.00 pg/mL. The 
NTproBNP is a marker of myocardial strain/stretch and a surrogate for HF that has been 
found to correlate with radiation dose to the heart in left-sided breast CA patients after 
RT(148) and in patients with lung CA.(216) An NTproBNP <125 pg/mL is considered 
normal and effectively rules out the presence of LV dysfunction.(146) 
Galectin-3 a novel mediator of HF development and progression(145) was 
measured with the Abbott ARCHITECT Galectin-3 assay (Abbott Laboratories, Abbott 
Park, IL) a chemiluminescent microparticle immunoassay for the quantitative 
determination of galectin-3 in human serum and EDTA plasma on the ARCHITECT i 
System. Galectin-3 is a galactoside-binding lectin expressed by macrophages during 
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phagocytosis and linked to the development of myocardial fibrosis.(217) An elevated Gal-
3 level (≥17.8 ng/mL) is indicative of increased cardiovascular risk.(218)   
High-sensitivity C-reactive protein is the prototypical inflammatory biomarker, and 
associated with worsening hemodynamics and outcomes in heart failure.(152) The 
hsCRP was determined using an ultrasensitive latex-enhanced immunoassay (Siemens 
Healthcare, Elangen, HR).(219) It has an analytical range of 0.175 to 20 mg/L with a CV 
of < 10%.  A low hsCRP level (<1 mg/L) is associated with a low cardiovascular risk.(220)  
 
Cardiac Magnetic Resonance Imaging 
Cardiac Magnetic Resonance imaging was performed on a Siemens Aera 1.5 
Tesla scanner (Siemens Healthcare, Elangen, HR) following a clinical assessment, 
measurement of renal function, a pregnancy test (if indicated), and completion of an 
MRI safety checklist. All studies were interpreted by a single experienced 
cardiovascular radiologist. For CMR, selected MRI sequences including cardiac 
dimensions (volumes and mass), systolic and diastolic function, and gadolinium-
contrast application was obtained. Cardiac Magnetic Resonance imaging is the gold-
standard for the assessment of ventricular function and volumes.(221) Delayed 
gadolinium enhancement imaging allows detection of myocardial fibrosis and scar and 
provides good diagnostic and prognostic value in cardiovascular diseases.(222) Areas 
of late-gadolinium enhancement (LGE) were considered a marker of myocardial injury.  
The time-1 (T1) relaxation is a measure in milliseconds of how quickly the net 
magnetization vector recovers to its ground state static magnetic field.(223) The 
concept of T1 mapping refers to pixelwise illustrations of absolute T1 relaxation times 
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on a map. Native T1 values are determined primarily by edema and an increase in 
interstitial space and myocardial T1 (native T1 myo) is prolonged in the presence of 
extracellular volume (ECV) expansion.(224) In gadolinium-enhanced T1 mapping (post-
contrast T1 myo), contrast is distributed throughout the extracellular space and shorten 
T1 relaxation times of myocardium proportional to the concentration of contrast-
agent.(225)  
The calculation of the ECV fraction requires measurements of myocardial and 
blood T1 before and after contrast administration along with the patient’s hematocrit 
value according to the following formula: 
 
Estimation of the ECV fraction was used to quantify diffuse myocardial injury.(226)  
  
Anthropometrics Assessment 
 Body composition was assessed pre-exercise via body mass index (BMI), waist 
and hip circumferences, and single-frequency bioelectrical impedance analysis (BIA) 
(Quantum II, RJL Systems, Inc., Clinton Township, MI) by experienced technicians. 
Body mass index was utilized to assess weight relative to height and calculated 
by the equation: BMI = kg/m2. Overweight was defined as a BMI of 25.0-29.9 kg/m2 and 
BMI ≥30.0 kg/m2 as obese.(227) Waist (above the iliac crest) and hip (maximal 
circumference of hip/proximal thigh, just below gluteal fold) circumferences were 
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obtained to characterize body fat distribution with a flexible tape measure on the skin 
surface in duplicate.(204)  
Bioelectrical impedance analysis has been validated as a measure of body 
adiposity when compared to reference methods such as dual X-ray 
absorptiometry.(228) Measurements were obtained prior to exercise in a fasted state 
with subjects on their current medications. Resistance and reactance (Xc) was 
calculated at a 50-kHz frequency at controlled room temperature with subjects placed in 
a supine position with arms and legs abducted approximately 45° to each other. Source 
electrodes were placed proximal to the metacarpophalangeal joint on the dorsal 
surfaces of the right hand and distal to the transverse arch on the superior surface of 
the right foot. Sensor electrodes were placed at the midpoint between the styloid 
processes and between the medial and lateral malleolus on the right ankle. Reactance 
and Xc were recorded to the nearest ohm and imputed into predictive equations to 
calculate fat mass (FM), fat-free mass (FFM), and total body water.(228) Fat mass and 
FFM was then indexed to height in meters squared. Percent body fat was calculated 
using FM and bodyweight in kilograms. 
  
Quality of Life and Physical Activity Questionnaires 
Two questionnaires were used to assess cancer-specific HRQOL 
and current levels of physical activity. The Functional Assessment of Cancer Therapy – 
General 7-item version (FACT-G7) is a validated HRQOL questionnaire with a scoring 
range of 0-28 and a mean value of 18.04  4.97 in healthy individuals wherein higher 
scores indicate better HRQOL that can be used with any tumor type.(229)  
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The International Physical Activity Questionnaire (IPAQ) – Short form is a 
validated instrument to assess physical activity levels in adults.(230) The IPAQ 
assesses subjective physical activity participation in the form of walking, moderate-
intensity, and vigorous-intensity activities weighted by energy requirements defined in 
metabolic equivalents (METS) taking into account frequency and duration to provide a 
volume of physical activity defined as MET-min/week.(230) Both questionnaires were 
administered by trained personnel prior to study procedures.  
 
Statistical Analysis 
 The objective of this pilot cross-sectional study was to determine the prevalence 
of exercise intolerance after chest irradiation, if exercise intolerance was related to 
markers of cardiac function, and if the “cardiac dose” – the amount of radiation the heart 
is exposed to – correlated with injury or dysfunction.  
Being the first study addressing the correlation of cardiac radiation dose with 
such parameters, it was not possible to estimate the sample size needed for statistical 
purposes. Given the design of this pilot study (single-cohort), the statistical analysis 
consisted primarily of descriptive statistics. A sample size of at least 29 subjects was 
considered to be required for a correlation coefficient >0.50 to demonstrate a moderate 
relationship between variables of interest with a power of 80% (=0.05) while 20 
subjects would provide a power of >95% for a correlation coefficient >0.70 (=0.05) 
reflecting a strong relationship. Continuous data are reported as median and 
interquartile range (IQR) or absolute range for potential deviation from a Gaussian 
distribution. Discrete variables are reported as a number and percentage. The 
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nonparametric Kruskal-Wallis test was used for comparisons between groups. The Chi 
square test was used to compare nominal level variables. Univariate analysis between 
CPET variables, cardiac biomarkers, and echo and CMR parameters was performed 
using the Spearman rank correlation coefficient test.  
Multivariate analysis using a linear regression model was performed using a 
stepwise approach including those variables associated with p<0.05 at univariate 
analysis from pre-specified cardiac, pulmonary, and body composition parameters to 
determine which predictor variables best explain peak VO2. Significant univariate 
predictors were assessed for multicollinearity prior to placement in the multivariate 
model. An additional correction for type of CA and for use of anthracyclines was 
performed by a mixed model of multivariate analysis using a General Linear Model. 
Statistical analysis was performed using SPSS version 24.0 (IBM Corp, Armonk, NY). 
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RESULTS 
Thirty subjects were enrolled between August 2016 - November 2017. During 
this time period 106 potential subjects were screened for study inclusion of which 76 
were not enrolled for the following reasons:  
1) 37 (35%) did not meet protocol minimum RT heart dose requirement;  
2) 27 (25%) were not interested;  
3) 5 (5%) failed to show up for their appointment;  
4) 5 (5%) had contraindications to undergo MRI;  
5) 2 (2%) had contraindication to undergo CPET.  
 Table 1 describes the clinical characteristics of the enrolled subjects which 
included 15 (50%) subjects who received RT for lung CA, 10 (33%) for breast CA, 2 
(7%) for esophageal CA, 1 (3%) for Hodgkin’s lymphoma, 1 (3%) for a desmoid tumor, 
and 1 (3%) for Castleman’s disease. The overall cohort was predominantly Caucasian 
(n=20 [67%]), mostly female (n=18 [60%]) with a median age of 63 (57-67) years. The 
median time since CA diagnosis was 2.6 years with a total range of 0.3 - 29.0 years. 
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Table 1: Clinical Characteristics of the Cohort. 
Variable Entire Cohort (N=30) 
Cancer type  
          Lung 15 (50%) 
          Breast 10 (33%) 
          Esophageal 2 (7%) 
          Hodgkin’s Lymphoma 1 (3%) 
Other diseases  
          Desmoid Tumor 1 (3%) 
          Castleman’s Disease 1 (3%) 
Caucasian 20 (67%) 
Female 18 (60%) 
Age (years) 63 (57-67) 
Time since Cancer Diagnosis (years) 2.6 (0.3-29.0)* 
Time since completion of Chemotherapy (years) 1.7 (0-21.8)* 
Prior chemotherapy 26 (87%) 
          Anthracycline-based chemotherapy 7 (24%) 
Time since completion of Radiotherapy (years) 2.0 (0.1-28.7)* 
Date are listed as median and (interquartile range), or total range*, or n (%). 
 
Non-small cell carcinoma was the primary lung CA type (13/15 [87%]) with the 
remaining 2 having small-cell carcinoma. The breast CA cohort (n=10) consisted of 
seven (70%) with left-sided disease and three (30%) with right-sided disease. Invasive 
ductal carcinoma was overwhelmingly the most common breast CA type (n=9/10 or 
90%) followed by one patient with an invasive lobular carcinoma. The prevalence of 
hormone receptor and HER2 status of the breast CA cohort was as follows: ER+ = 8/10 
(80%), PR+ = 7/10 (70%), HER2+ = 2/10 (20%). Table 2 provides a detailed breakdown 
of CA stage by diagnosis (breast CA or lung CA and other diseases).    
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Table 2: Cancer Stage of Study Participants. 
Stage Breast CA 
n=10 
Lung CA or other 
diseases 
n=20 
IA 1 (10%) 1 (5%) 
IB 1 (10%)  
II 1 (10%)  
IIA  1 (5%) 
IIB 1 (10%) 1 (5%) 
IIIA 3 (30%) 10 (50%) 
IIIB 2 (20%) 4 (20%) 
IIIC 1 (10%)  
Unknown  3 (15%) 
 
Fifteen (50%) of all patients (breast CA =10 (100%), lung CA or other diseases = 
5 (25%) had previously undergone surgery. Twenty-six (87%) of all patients (breast CA 
= 9 (90%), lung CA or other diseases = 17 (85%) had previously undergone neo-
adjuvant, adjuvant, or concurrent chemotherapy. Specifically, seven (70%) of the breast 
CA patients underwent neo-adjuvant chemotherapy, and 2 (20%) underwent adjuvant 
chemotherapy. Twelve (60%) of the lung CA or other disease patients underwent 
concurrent chemoradiation followed by 3 (15%) who underwent adjuvant chemotherapy, 
and 2 (10%) who underwent neo-adjuvant chemotherapy. Seven (24%) of the total 
cohort underwent regimens including anthracyclines which included 6/7 breast CA 
patients and one patient with Hodgkin’s lymphoma. Table 3 lists the types of 
chemotherapy, frequency of use, and average doses of the cohort. Seven (70%) of the 
breast CA patients were on concomitant hormonal therapy at the time of evaluation. 
Time since completion of chemo was 1.7 years with a total range of 0.1-28.7 years. 
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Table 3: Chemotherapy Regimens of the Cohort.  
Chemotherapy Type n (%) Dose  
Taxol  18 (60%) 483  289 mg/m2 
Carboplatin 13 (43%) 863  636 mg 
Cyclophosphamide 8 (27%) 2540  523 mg/m2 
Doxorubicin 7 (23%) 234  44 mg/m2 
Cisplatin 5 (17%) 271  82 mg 
Etoposide 4 (13%) 597  248 mg/m2 
Pemetrexed 2 (7%) 1500  707 mg/m2 
Imatinib 1 (3%) 300 mg 
Rituximab 1 (3%) 375 mg/m2 every 3-months 
Nivolumab 1 (3%) 2240 mg 
Trastuzumab 1 (3%) 104 mg/kg 
Pertuzumab 1 (3%) 1260 mg/kg 
Vinblastine 1 (3%) 36 mg/m2 
Dacarbazine 1 (3%) 2250 mg/m2 
Bleomycin 1 (3%) 60 u/m2 
Data are listed as n (%) and mean  standard deviation.   
Abbreviations: mg/m2=milligrams per meter squared. 
 
All patients had previously undergone neo-adjuvant/adjuvant or concurrent RT 
with a median duration of 2.0 years with an absolute range of 0.1 - 28.7 years since end 
of RT treatment. Seventeen (85%) of the lung CA and other diseases group underwent 
primary RT, 2 (10%) underwent adjuvant RT followed by 1 (5%) who underwent neo-
adjuvant RT. The median number of RT fractions was 30 (range = 4-35) with a median 
of 2.0 (range = 1.5-12.0) Gy per fraction for a prescribed RT dose of 60.0 (range = 30.4-
70.0) Gy. Five of these subjects also had additional previous RT treatments (#fractions 
= 4 [range = 4-20], Gy per fraction = 12.0 [range = 1.8-12.0] Gy, total prescribed dose = 
48.0 [range = 32.0-60.0]) Gy.  
 The median number of RT fractions for the breast CA subjects was 32 (range = 
16-33) with a median of 2.0 (range = 1.8-2.7) Gy per fraction for a prescribed RT dose 
of 60.2 (range = 42.6-66.0) Gy. One of the breast CA patients also had additional 
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previous RT treatments (#fractions = 28, Gy per fraction = 1.8 Gy, total prescribed dose 
= 50.4 Gy).  
The MCRD and MLRD, reflective of the dose contributions from all RT treatments 
for each patient, for the entire cohort was 5.6 (3.7-17.8) and 9.4 (6.4-14.5) Gy, 
respectively. Specific to CA type, the MCRD for the lung CA and other diseases was 
12.4 (range = 3.1-42.0) Gy and the MLRD was 12.7 (range = 3.3-21.5) Gy. The MCRD 
for breast CA patients was 3.7 (range = 1.9-5.5) Gy while the MLRD was 6.9 (range = 
0.5-14.7) Gy, respectively. Table 4 lists the MCRD, MLRD, mean %heart and lung 
volumes that received at least 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy, 
respectively. When separating the CA types (breast vs. lung CA and other diseases) 
there was a significant difference in MCRD, and the %heart volume receiving at least 5 
Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, and 50 Gy (all P’s≤0.02) with the lung Ca and other 
diseases subjects receiving higher heart doses than breast CA patients. 
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Cardiovascular Risk and Comorbidity Status 
 Hypertension was the primary established CVD risk factor (n=17 [57%]) followed 
by hypercholesterolemia. Table 5 lists the prevalence of CVD risk factors and 
cardiovascular medication use amongst the group. Lung disease was the most common 
non-CVD-related comorbidity present in 17 (57%) individuals. All subjects were Eastern 
Cooperative Oncology Group (ECOG) status 0-1 with a mean Karnofsky grade of 
9010.     
 
Table 4: Heart & Lung Radiotherapy Volumes.  
 Entire Cohort 
N=30 
Breast CA 
n=10 
Lung Ca and 
Other Diseases 
n=20 
 
P-value 
Heart Volumes    
MCRD 5.6 (3.7-17.8) 3.7 (2.8-4.3) 12.4 (5.5-24.9) <0.001 
V5 Gy 39.5 (15.8-80.5) 13.5 (11.5-30.0) 62.0 (36.5-87.2) <0.001 
V10 Gy 19.3 (8.8-67.3) 8.2 (2.8-9.0) 40.0 (18.0-73.8) <0.001 
V20 Gy 7.0 (1.2-35.0) 1.6 (0.8-3.5) 24.0 (7.0-60.3) <0.01 
V30 Gy 2.5 (0-15.0) 0.1 (0-2.3) 5.1 (0.1-26.5) 0.02 
V40 Gy 1.0 (0-7.8) 0 (0-1.0) 2.5 (0-12.8) 0.01 
V50 Gy 0 (0-3.0) 0 (0-0) 0.5 (0-5.5) <0.01 
Lung Volumes     
MLRD 9.4 (6.4-14.5) 6.9 (5.7-10.4) 12.7 (7.6-16.6) 0.06 
V5 Gy 42.0 (25.7-60.0) 27.4 (17.0-39.7) 54.0 (29.0-66.5) 0.01 
V10 Gy 28.7 (20.0-36.8) 20.5 (13.3-29.9) 33.0 (23.5-43.5) 0.02 
V20 Gy 17.0 (11.3-25.8) 13.6 (11.3-20.1) 18.5 (10.8-26.5) 0.28 
V30 Gy 11.9 (5.5-18.0) 9.8 (7.0-13.5) 13.0 (4.0-18.5) 0.53 
V40 Gy 7.0 (3.0-11.0) 5.7 (3.5-9.0) 10.0 (2.8-14.0) 0.46 
V50 Gy 2.0 (1.0-6.8) 1.2 (0-2.0) 4.0 (1.0-9.5) 0.03 
Values are listed as median and (interquartile range). 
Abbreviations: MCRD=mean cardiac radiation dose; V=percent volume of the heart; Gy=Gray 
units; MLRD=mean lung radiation dose. 
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Anthropometrics Assessment 
 Nineteen (63%) subjects met BMI criteria for overweight (9 [30%]) or obesity (10 
[33%]). Anthropometrics of the group are detailed in Table 6.  
Table 6: Anthropometrics of the Cohort. 
Variable Entire Cohort (N=30) 
Weight (kg) 76.1 (62.2-85.2) 
Body Mass Index (kg/m2) 27.1 (23.6-30.6) 
Waist Circumference (cm) 96 (84-106) 
Waist/Hip Ratio 0.86 (0.83-0.95) 
Fat Mass % 33 (23-40) 
Fat Mass (kg) 23.1 (15.3-33.1) 
Fat Mass Index 8.7 (5.3-12.1) 
Fat-Free Mass % 66 (60-77) 
Fat-Free Mass (kg) 51.0 (44.2-60.1) 
Fat-Free Mass Index 18.4 (16.6-20.2) 
Data are listed as median and (interquartile range). 
Abbreviations: kg=kilograms; kg/m2=kilograms per meter squared; cm=centimeters. 
 
 
Table 5: Prevalence of Established Cardiovascular Disease Risk Factors and 
Cardiovascular Medication Usage.  
Cardiovascular Disease Risk Factors N (%) 
     Hypertension 17 (57%) 
     Diabetes Mellitus-Type II 7 (23%) 
     Hypercholesterolemia 14 (47%) 
     Early Family History of Cardiovascular Disease 9 (30%) 
     Current Smoker 6 (20%) 
     Obesity (Body Mass Index > 30) 10 (33%) 
     Sedentary Lifestyle 12 (40%) 
Cardiovascular Medications 
     Beta-blockers 5 (17%) 
     Angiotensin blockers 6 (20%) 
     Aldosterone inhibitors 2 (7%) 
     Statins 10 (33%) 
     Calcium channel blockers 5 (17%) 
     Diuretics 12 (40%) 
          Thiazide diuretics           7/12 (58%) 
           Loop diuretics           5/12 (42%) 
     Anti-platelets 13 (43%) 
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Cardiopulmonary Exercise Testing (CPET) 
The peak VO2 for the entire cohort was 1376 (1057-1552) mL·min-1, normalized 
to bodyweight was 16.9 (14.4-20.8) mL·kg-1·min-1 or moderately reduced at 62 (52-89) 
% of predicted values based upon age/gender/anthropometrics-based normative 
values. Table 7 provides a comprehensive summary of the CPET variables analyzed 
with this study. As expected peak VO2 was inversely correlated with age (R=-0.401, 
P=0.031). Peak VO2 was not significantly different with regards to gender (P=0.116) or 
race (P=0.556). However, it was significantly higher (P=0.008) in the breast CA cohort 
compared with the lung CA and other diseases (21.0 [17.8-23.6] mL·kg-1·min-1 versus 
16.0 [13.0-18.6] mL·kg-1·min-1) or 93 (77-98) %predicted versus 54 (48-68) %predicted. 
Peak VO2 was not significantly different when comparing those who underwent 
chemotherapy of any type (P=0.66) versus those who did not undergo chemotherapy. 
Peak VO2 was significantly higher (P=0.021) in those who underwent ACT regimens 
(22.0 [16.2-23.2] versus 16.6 [14.4-19.6] mL·kg-1·min-1) although it did not correlate with 
anthracycline dose when treated as a continuous variable (R=0.535, P>0.2). 
 The median peak RER was 1.02 (0.95-1.09) with 16/30 (53%) achieving an RER 
≥ 1.0, 12/30 (40%) reaching an RER ≥ 1.05, and 12/30 (40%) reaching an RER ≥ 1.10, 
respectively. The primary reason for test termination was dyspnea (43%) followed by 
fatigue (30%) with 27% stopping for other reasons (musculoskeletal limitations, 
lightheaded/dizziness). 
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Table 7: Cardiopulmonary Exercise Test Variables. 
CPET Variables Entire Cohort 
Absolute Peak VO2 (mL·min-1) 1376 (1057-1552) 
     Percent-predicted Absolute Peak VO2 (%) 62 (51-98) 
Relative VO2 (mL·kg-1·min-1) 16.9 (14.4-20.8) 
     Percent-predicted Relative VO2 (%) 62 (52-89) 
     Relative Peak VO2 <83% predicted 22 (73%) 
METS 4.8 (4.1-5.9) 
Oxygen Pulse (mL/beat) 9.2 (7.5-10.7) 
     Percent-predicted Oxygen Pulse (%) 82 (66-96) 
     Oxygen Pulse <85% predicted 13 (45%) 
Ventilatory Anaerobic Threshold (mL·min-1) 1040 (842-1234) 
     Percent-predicted VAT (%) 53 (44-70) 
Ventilatory Anaerobic Threshold (mL·kg-1·min-1) 13.5 (11.4-14.7) 
     Percent-predicted VAT (%) 54 (43-59) 
VE/VCO2 Slope 32.4 (27.9-35.5) 
VE/VCO2/VO2 ratio 1.69 (1.40-2.48) 
OUES 1.58 (1.38-1.97) 
OUEP 37 (30.5-42.0) 
Peak RER 1.02 (0.95-1.09) 
Exercise Time (minutes) 9.5 (7.9-12.0) 
Resting Heart Rate (bpm) 73 (68-86) 
Maximal Heart Rate (bpm) 150 (122-164) 
Percent-predicted APMHR (%) 91 (79-100) 
Chronotropic Index  1.10 (0.92-1.39) 
Heart Rate Recovery-1 (bpm) 20 (13-26) 
Resting Systolic BP (mmHg) 124 (111-143) 
Resting Diastolic BP (mmHg) 70 (63-81) 
Max Systolic BP (mmHg) 174 (155-190) 
Max Diastolic BP (mmHg) 70 (70-80) 
Rate-Pressure Product (Systolic mmHg x HR) 24.0 (19.7-29.8) 
Resting SPO2 (%) 99 (98-100) 
Exercise SPO2 (%) 97 (95-99) 
 SPO2 exercise 1 (0-4) 
VE/MVV ratio 0.67 (0.54-0.78) 
Breathing reserve (Liters) 23.0 (12.1-41.5) 
Peak Minute Ventilation (L·min-1) 47.7 (42.2-53.1) 
Peak Respiratory Rate (breaths·min-1) 36 (31-42) 
Peak Tidal Volume (Liters) 1.26 (1.03-1.62) 
Data are listed as median and (interquartile range) or n (%). 
Abbreviations: VO2=oxygen consumption; METS=metabolic equivalents; VAT=ventilatory anaerobic 
threshold; VE/VCO2=minute ventilation to carbon dioxide production; OUES=oxygen uptake efficiency 
slope; OUEP=oxygen uptake efficiency plateau; RER=respiratory exchange ratio; APMHR=age-predicted 
maximal heart rate, SPO2=oxygen saturation; VE/MVV=peak minute ventilation/maximal voluntary 
ventilation ratio. 
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Pulmonary Function Results 
 The majority of the cohort (n=16 [53%]) did not show evidence of any significant 
airflow limitation while the remaining subjects were graded according to GOLD criteria 
as follows: Grade 1 (Mild) = 2 (7%); Grade 2 (Moderate) = 7 (23%); Grade 3 (Severe) = 
4 (13%); Grade 4 (Very Severe) = 1 (3%). Presence of airflow limitation was not 
identified in the breast CA patients and was predominantly confined to those with lung 
CA (n=13/14 [93%] of the remaining cohort). Table 8 provides a detailed assessment of 
spirometry values for the entire cohort. 
 
Table 8: Pulmonary Function Results of the Cohort. 
Variables Entire Cohort (N=30) 
Forced Vital Capacity (Liters) 2.80 (2.39-3.40) 
     FVC% 83 (74-97) 
Forced Expiratory Volume 1-second (Liters) 2.01 (1.50-2.46) 
     FEV1% 75 (55-95) 
FEV1/FVC ratio 0.72 (0.57-0.79) 
Forced Expiratory Flow 25-75% 1.33 (0.85-2.26) 
     FEF% 51 (31-95) 
Peak Expiratory Flow (L/Sec) 4.61 (3.29-5.80) 
     PEF% 67 (46-98) 
Direct MVV (Liters per minute) 72.4 (54.2-95.6) 
     MVV% 78 (45-92) 
Data are listed as median and (interquartile range). 
Abbreviations: FVC=Forced vital capacity; FEV1=Forced expiratory volume in 1-second; 
FEF=Forced expiratory flow; PEF=Peak expiratory flow; MVV=Maximal voluntary 
ventilation. 
 
Doppler Echocardiography 
 Two-dimensional echocardiography revealed half of the subjects (n=15 [50%]) 
had an LVEF (52 (47-60)%) less than the lower limit of the normal reference range (53-
73%, mean2-standard deviations [SD]). Using European Society of Cardiology (ESC) 
criteria(231): two patients had a reduced LVEF (<40%), seven had a mid-range LVEF 
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(≥40% - 49%) with the remaining having LVEF’s ≥50%. Thirteen (43%) patients met 
criteria for diastolic dysfunction based upon ESC recommendations defined as at least 
two of the following to be present: functional alterations of - E/e’>13; or mean e’ <9 
cm/s; or structural alterations of - left-atrial volume index (LAVI) >34 mL/m2; or left-
ventricular hypertrophy.(231) Furthermore, when using the ESC Diagnostic algorithm 
for a diagnosis of heart failure of non-acute onset and assigning exercise 
intolerance as a typical symptom of HF with the exposition to cardiotoxic drug/radiation 
as an assessment of HF probability the prevalence of HFpEF was 21% in the cohort 
evidenced by a NTproBNP ≥125 pg/mL and the aforementioned echo diastolic 
dysfunction criteria with a preserved LVEF (≥50%). Table 9 provides a detailed 
summary of the Doppler echocardiographic variables of the entire cohort. In univariate 
analysis, the echo-derived resting e’ (R=-0.562, P=0.024), and stress echo  VTICO 
exercise (R=-0.521, P=0.046) both correlated with the MCRD. 
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Table 9: Echocardio-Doppler Parameters. 
Variables Entire Cohort (N=30) 
Left-ventricular ejection fraction (%) 52 (47-60) 
LVEDV (mL) 83 (70-102) 
LVESV (mL) 41 (30-51) 
Stroke Volume (mL) 44 (36-52) 
LVEDV Index (mL) 45 (39-56) 
LVESV Index (mL) 22 (16-26) 
Stroke Volume Index (mL/m2) 23 (19-29) 
E (cm/s) 74.1 (62.3-87.3) 
A (cm/s) 86.5 (72.5-94.2) 
E/A ratio 0.89 (0.72-1.03) 
LAVI (mL/m2) 21.2 (17.1-28.1) 
e’ (cm/s) 8.0 (7.1-9.6) 
s’ (cm/s) 7.9 (7.1-8.7) 
a’ (cm/s) 10.3 (8.2-11.4) 
Deceleration time (ms) 215 (172-244) 
E/e’ 8.9 (7.0-12.8) 
e’/DT 0.039 (0.031-0.046) 
Exercise E (cm/s) 100 (76-123) 
Exercise e’ (cm/s) 10.7 (7.8-14.9) 
 e’exercise (cm/s) 1.3 (-0.5-5.3) 
Exercise E/e’ 7.9 (7.0-13.5) 
 E/e’exercise 0.4 (-2.8-1.9) 
DFRI (e′rest•Δe′exercise) 12.5 (-3.8-48.7) 
LVOT VTI – Rest (cm) 16.6 (14.4-20.4) 
LVOT VTI – Exercise (cm) 19.5 (17.5-25.0) 
 LVOT VTIexercise 3.1 (2.1-5.9) 
Data are listed median and (interquartile range). 
Abbreviations: LVEDV=left-ventricular end-diastolic volume; LVESV=left-ventricular end-systolic 
volume; E=early transmitral velocity; A=late transmitral velocity; LAVI=left-atrial volume index; e’= early 
diastolic mitral annular velocity; s’=longitudinal systolic strain; a’=late diastolic myocardial velocity; 
E/e’=ratio of early transmitral velocity to early diastolic mitral annular velocity; e’/DT=ratio of early 
diastolic mitral annular velocity to deceleration time; DFRI= diastolic functional reserve index; 
cm/s=centimeters per second; ms=milliseconds; LVOT VTI=left-ventricular outflow tract velocity time 
integral. 
  
Cardiac-specific Blood-based Biomarker Assessment 
 Table 10 indicates the proportion of the cohort with abnormal responses for each 
blood-based biomarker and the median values for each. Elevated hsCRP and 
NTproBNP was noted in over half of all subjects. The cardiac troponins hs-cTnI and hs-
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cTnT were detected in 28/30 (93%) and 29/30 (unable to detect hs-cTnT in 1-subject 
due to hemolysis) (97%) of all subjects, respectively. 
 
Table 10: Cardiac-specific Blood-based Biomarkers. 
Biomarker Abnormal Response Values 
NTproBNP (pg/mL) 18 (60%) 187 (51-310) 
hsCRP (mg/L) 19 (63%) 2.9 (1.5-6.2) 
Galectin-3 (ng/mL) 10 (33%) 15.0 (13.3-18.8) 
hs-cTnT (ng/L) 5 (17%) 9.05 (5.28-12.79) 
hs-cTnI (ng/L) 3 (10%) 3.00 (2.00-6.50) 
Legend: Date are listed as n (%) or median and (interquartile range). Abnormal 
response was defined as: NTproBNP ≥125 pg/mL, hsCRP >2 mg/L, Galectin-3 >17.8 
ng/mL, hs-cTnT >22ng/L-Male and >14ng/L-Female, hs-cTnI >14ng/L-Male and 
>11.1ng/L-Female. 
 
Abbreviations: NTproBNP=N-terminal pro-brain natriuretic peptide; pg/mL=picograms per milliliter; 
hsCRP=high-sensitivity C-reactive protein; mg/L=milligrams per liter; hs-cTnT=high-sensitivity cardiac 
troponin T; ng/L=nanograms per liter; hs-cTnI=high-sensitivity cardiac troponin I; ng/mL=nanograms 
per milliliter. 
 
 
Health-Related Quality of Life and Physical Activity Questionnaires 
 The median FACT-G7 was within a normal range with a score 20 (15.0-23.5). 
FACT-G7 scores did not significantly correlate with peak VO2, echo parameters, cardiac 
biomarkers, or CMR variables (all P’s>0.06). The median IPAQ score was 792 (330-
1689) MET-min/week and the distribution of physical activity (PA) according to IPAQ 
categories was as follows: Category-1 (Inactive) = 40%, Category-2 (Minimally Active) = 
40%, Category-3 (Highly Activity) = 20%.  The IPAQ-derived MET-min/week as a 
continuous variable or PA categories did not correlate with peak VO2 (R=0.207, 
P=0.282) and (R=0.145, P=0.452), respectively. However, the FACT-G7 score did 
demonstrate a significant positive relationship with the IPAQ-derived volume of PA 
(R=0.423, P=0.02). 
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Cardiac Magnetic Resonance Imaging 
 Using CMR assessment of LVEF: 8 (27%) had an LVEF below the lower limit of 
normal (<57%, mean  2SD) and 2 (7%) had an LVEF greater than the upper limit of 
normal (>77%, mean  2SD).(232) The CMR LVEF, ECV, left-ventricular end-diastolic 
volume (LVEDV), left-ventricular end-systolic volume (LVESV), SV, SV index (SVI), 
LGE, or myocardial T1 mapping (pre- and post-contrast) did not correlate with MCRD 
(all R’s<0.31, P’s>0.12) or peak VO2 (all R’s<0.3, P’s>0.08). Table 11 provides a 
detailed description of the CMR variables of interest. 
Table 11: Cardiac Magnetic Resonance Imaging Parameters. 
Variables Entire Cohort (N=30) 
Left-ventricular ejection fraction (%) 64 (53-74) 
LVEDV (mL) 117.2 (93.6-136.6) 
LVESV (mL) 40.5 (31.1-62.0) 
LV Stroke Volume (mL) 68.2 (54.9-80.6) 
LV Stroke Volume Index (mL/m2) 38.0 (31.0-43.8) 
Presence of late-gadolinium enhancement 12 (41%) 
Myocardial T1 Mapping (ms) 1030 (1016-1067) 
Post-contrast myocardial T1 Mapping (ms) 442 (416-466) 
Extracellular Volume (%) 26.9 (24.8-29.2) 
Data are listed as median and (interquartile range) or n (%). 
Abbreviations: LVEDV=left-ventricular end-diastolic volume; LVESV=left-ventricular end-systolic 
volume; mL=milliliter; mL/m2=milliliters per meter squared; ms=milliseconds. 
 
 
Limitation to Exercise 
 Normal aerobic exercise capacity was observed in 8 (27%) subjects evidenced 
as a peak VO2 above 83% of predicted per age, sex, height, and weight. In the 
remaining 22 (73%) of subjects with a reduced peak VO2 <83% of predicted, 9 (30%) 
demonstrated a predominant CV limitation, 8 (27%) a pulmonary limitation, and 5 (17%) 
a non-cardiopulmonary or indeterminate limitation to exercise. Table 12 details the 
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comparison of groups based upon aerobic exercise capacity and the predominant 
limitation to exercise. There were significant differences between the groups in CA type 
(x2=[3, n=30] 16.7, P<0.01), peak VO2 (P<0.01), FEV1 (P<0.01), and MCRD (P=0.03).  
 Between group comparisons using Bonferroni correction of continuous variables 
revealed peak VO2 was significantly higher in those with normal exercise capacity 
relative to those with a predominant pulmonary limitation (P<0.01) or those with a 
predominant cardiac limitation to exercise (P<0.01). The FEV1 was significantly higher 
in the normal aerobic exercise capacity group compared to those with a pulmonary 
limitation (P<0.01). Furthermore, the MCRD was lower in those with normal aerobic 
exercise capacity compared to those with a pulmonary limitation (P=0.05).  
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Table 12: Comparison of groups based upon limitation to exercise. 
 Normal 
Exercise 
Capacity 
(n=8) 
CV 
Limitation 
(n=9) 
Pulmonary 
Limitation 
(n=8) 
Indeterminate 
Limitation 
(n=5) 
P-
value 
Age (years) 59.5 
(49.5-67.5) 
59.0 
(49.0-65.0) 
63.5 
(57.5-72.3) 
64.0 
(61.5) 
0.42 
Female 8 (100%) 4 (44%) 3 (38%) 3 (60%) 0.05 
Breast CA 7 (88%) 1 (11%) 0 (0%) 2 (40%) <0.01 
Peak VO2 22.8  
(20.5-25.0) 
16.0 
(13.7-17.6) 
15.5 
(11.7-18.8) 
16.5 
(13.7-18.5) 
<0.01 
BMI (kg/m2) 27.0 
(22.9-30.6) 
25.1 
(19.7-30.2) 
26.3 
(23.6-28.0) 
36.9 
(29.5-46.2) 
0.08 
FEV1 (Liters) 2.35 
(2.10-2.72) 
2.11 
(1.49-2.53) 
1.12 
(0.87-1.86) 
1.90 
(1.74-2.59) 
<0.01 
MRI LVEF (%) 65 
(63-75) 
59 
(53-68) 
60 
(46-73) 
73 
(54-78) 
0.34 
Chemotherapy 7 (88%) 9 (100%) 5 (63%) 5 (100%) 0.11 
MCRD (Gy) 3.5  
(2.7-5.1) 
10.3  
(4.0-22.6) 
12.3 
(5.2-26.5) 
10.7 
(4.4-20.3) 
0.03 
Time since RT  
(years) 
1.5  
(0.7-2.5) 
1.8  
(0.4-4.0) 
5.2  
(1.7-7.8) 
0.5  
(0.2-2.6) 
0.16 
Hypertension  4 (50% 6 (67%) 3 (38%) 4 (80%) 0.44 
Dyslipidemia  4 (50%) 5 (56%) 4 (50%) 4 (50%) 0.42 
Diabetes 3 (38%) 1 (11%) 1 (13%) 3 (38%) 0.63 
Obesity 3 (38%) 3 (33%) 1 (13%) 3 (60%) 0.37 
Smoking 0 (0%) 1 (11%) 4 (50%) 1 (20%) 0.08 
MET-min/week 1689 
(1064-4467) 
462 
(132-983) 
662 
(26-924) 
2523 
(468-8025) 
0.09 
Data are listed as median and (interquartile range) or n (%). 
Abbreviations: CA=cancer; VO2=oxygen consumption; BMI=body mass index; FEV1=forced expiratory 
volume in 1-second; MRI=magnetic resonance imaging; LVEF=left-ventricular ejection fraction; 
MCRD=mean cardiac radiation dose; Gy=Gray units; RT=radiotherapy; MET=metabolic equivalent. 
 
Predictors of Peak Oxygen Uptake 
 An assessment of pre-specified physiologic predictors of peak VO2 listed in 
Table 13 at univariate analysis revealed significant associations with RT, cardiac, body 
composition, and ventilatory parameters and includes the variables retained in a 
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multivariate analysis model. The MCRD demonstrated a significant inverse association 
(Figure 2) with peak VO2 (R=-0.380, P=0.04), but total prescribed radiation dose or 
MLRD did not reveal a significant relationship.  
The cardiac parameters e’, E/e’, E/e’ exercise, e’/DT ratio, DFRI, VTICO exercise, 
NTproBNP, hs-cTnI, and hs-cTnT were all significantly associated with peak VO2 in the 
entire cohort. The waist/hip ratio was the only body composition parameter that 
demonstrated a significant correlation with peak VO2 (R=-0.431, P=0.03). The 
ventilatory parameters FVC, FEV1, FEV1/FVC, MVV, and SPO2 with exercise were all 
associated with peak VO2 at univariate analysis. 
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Figure 2. Relationship of peak VO2 to the mean cardiac radiation dose. 
Abbreviations: VO2=oxygen consumption; MCRD=mean cardiac radiation dose; Gy=Gray units. 
 
 
  
R=-0.380, P=0.04
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 Pre-specified cardiac, pulmonary, and body composition parameters that 
demonstrated a significant relationship to peak VO2 (P<0.05) were entered into a 
stepwise multivariate regression model that revealed the DFRI and NTproBNP were 
both independent predictors of peak VO2 in the entire cohort (R2=0.73, P<0.01; DFRI -  
ß=0.765, P<0.01; NTproBNP - ß =-0.389, P=0.04). 
 The DFRI and NTproBNP were then entered into a general linear model with the 
addition of two potential categorical predictors: 1) CA-type (breast vs. lung and other 
diseases) and 2) use of anthracycline-based chemotherapy (yes or no). This resulted in 
the loss of NTproBNP as an independent predictor (P=0.06), but the DFRI remained 
strongly associated with peak VO2 (R2=0.74, P<0.01).  
 The DFRI reflects the velocity of myocardial relaxation at rest and with exercise. The 
strong association between DFRI and peak VO2 supports a central role of impaired left 
ventricular diastolic reserve in the pathophysiology of radiation-induced exercise 
intolerance. 
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Table 13: Multivariate Analysis of Predictors of Peak VO2 for the Entire Cohort. 
Variable R-value Univariate P-value Multivariate P-value 
Radiotherapy Parameters 
Total Prescribed Dose (Gy) 0.610 0.76  
MCRD (Gy) -0.380 0.04 0.64 
MLRD (Gy) 0.123 0.54  
Cardiac Parameters 
MRI LVEF (%) 0.050 0.80  
ECV (%) -0.177 0.39  
Rest e’ 0.494 <0.01 0.76 
E/e’ -0.552 <0.01 0.31 
 e’exercise 0.644 <0.01 0.41 
Exercise e’ 0.574 0.02 0.58 
Exercise E/e’ -0.487 0.08  
 E/e’exercise -0.329 0.21  
e’/DT ratio 0.427 0.02 0.58 
DFRI 0.693 <0.01 <0.01 
Exercise VTICO 0.200 0.46  
 VTICO exercise 0.614 0.02 0.86 
NTproBNP -0.590 <0.01 0.04 
hs-cTnI -0.515 <0.01 0.66 
hs-cTnT -0.550 <0.01 0.57 
Galectin-3 -0.279 0.14  
hsCRP -0.301 0.11  
Body Composition Parameters 
Weight (kg) -0.157 0.42  
BMI -0.051 0.80  
Waist Circumference -0.368 0.06  
W/H Ratio -0.431 0.03 0.82 
Fat Mass% -0.008 0.97  
Fat Mass Index -0.013 0.95  
Fat-Free Mass% -0.005 0.98  
Fat-Free Mass Index -0.186 0.33  
Ventilatory Parameters 
FVC 0.469 0.01 0.54 
FEV1 0.673 <0.01 0.16 
FEV1/FVC 0.550 <0.01 0.21 
Direct MVV 0.600 <0.01 0.07 
 SPO2 exercise -0.429 0.02 0.70 
Abbreviations: Gy=Gray; MCRD=mean cardiac radiation dose; MLRD=mean lung radiation dose; 
LVEF=left-ventricular ejection fraction; e’=early diastolic mitral annular velocity; E/e’=ratio of early 
transmitral velocity to early diastolic mitral annular velocity; =delta; e’/DT=ratio of early diastolic mitral 
annular velocity to deceleration time; DFRI= diastolic functional reserve index; VTICO =left-ventricular 
outflow tract velocity time integral cardiac output; NTproBNP=N-terminal pro-brain natriuretic peptide; 
hs-cTnT=high-sensitivity cardiac troponin T; hs-cTnI=high-sensitivity cardiac troponin I; hsCRP=high-
sensitivity C-reactive protein; kg=kilograms; BMI=body mass index; W/H=waist/hip; FVC=Forced vital 
capacity; FEV1=Forced expiratory volume in 1-second; MVV=Maximal voluntary ventilation; 
SPO2=oxygen saturation. 
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Predictors of peak VO2 according to primary cause of limitation. 
 Dividing the cohort by primary exercise limitation (cardiac vs. pulmonary vs. 
other) and examining the predictors of peak VO2 in each group revealed the relationship 
between MCRD and peak VO2 was further strengthened (Figure 3) (R=-0.569, P=0.02) 
in those with a primary cardiac limitation to exercise. Doppler-derived stress echo 
diastolic parameters (e’ with exercise, exercise e’, DFRI), cardiac-specific biomarkers 
(NTproBNP, hs-cTnT), and pulmonary function (FEV1, MVV) were also univariate 
predictors of peak VO2 (Table 14). None of the body composition parameters correlated 
with peak VO2 in those with a cardiac limitation to exercise. A multivariate stepwise 
regression model created using significant univariate predictors (P<0.05) revealed that 
the variable: exercise e’ was an independent predictor of peak VO2 (R=0.785, P=0.01). 
Exercise e’ reflects the velocity of myocardial relaxation with exercise. Also, in this 
subgroup, the strong association between diastolic reserve and peak VO2 support its central 
role of in the pathophysiology of radiation-induced exercise intolerance. 
 Those limited predominantly by a pulmonary limitation to exercise also 
demonstrated significant associations between peak VO2 and Doppler-derived 
rest/stress echo diastolic parameters (e’, E/e’, e’ exercise, exercise e’, exercise E/e’, 
E/e’ exercise, DFRI, exercise VTICO,  VTICO exercise), cardiac-specific biomarkers (hs-cTnI, 
Gal-3), and pulmonary function (MVV, SPO2exercise) parameters (Table 15). None of 
the body composition parameters correlated with peak VO2 in those with a primary 
pulmonary limitation to exercise. In a multivariate model, only the echo-Doppler diastolic 
parameter, exercise E/e’ reflective of the increase in LV filling pressure with exercise was 
an independent predictor of peak VO2 (R=1.00, P<0.001). Also, in this subgroup with 
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pulmonary limitation, the strong inverse association between diastolic function and peak 
VO2 support its central role of in the pathophysiology of radiation-induced exercise 
intolerance. 
 In those with an indeterminate or non-cardiopulmonary limitation to exercise only 
the Doppler-derived echo diastolic parameter: resting E/e’ and hsCRP were univariately 
associated with peak VO2. However, due to the small size of the sample (n=5) 
multivariate analysis was not performed.  
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Figure 3. Relationship of peak VO2 to the mean cardiac radiation dose in individuals 
with a predominant cardiac limitation to exercise. 
Abbreviations: VO2=oxygen consumption; MCRD=mean cardiac radiation dose; Gy=Gray units. 
 
  
R=-0.569, P=0.02
 
93 
 
 
 
Exploratory Analysis: Relationship of Other CPET Variables to Mean Cardiac 
Radiation Dose. 
 
 In addition to peak VO2, numerous other CPET-derived variables correlated with 
radiation doses.  
Peak VO2 in absolute values (mL·min-1) moderately correlated with MCRD (R=-
0.432, P=0.019), V5Gy (R=-0.434, P=0.019), and V10Gy (R=-0.470, P=0.010). Percent-
predicted peak VO2 demonstrated a significant inverse relationship with MCRD (R=-
0.471, P=0.010), V5Gy (R=-0.453, P=0.014), V10Gy (R=-0.489, P=0.007), V20Gy (R=-
0.413, P=0.026, and V40Gy (R=-0.369, P=0.045).  
The peak %-predicted O2 pulse was inversely associated with all RT doses: 
MCRD (R=-0.505, P=0.005), V5Gy (R=-0.514, P=0.004), V10Gy (R=-0.561, P=0.002), 
V20Gy (R=-0.452, P=0.014), V30Gy (R=-0.476, P=0.009), V40Gy (R=-0.536, P=0.003), 
and V50Gy (R=-0.420, P=0.023). 
The OUEP and %-predicted OUEP also demonstrated significant inverse 
associations with MCRD ([R=-0.419, P=0.024], V5Gy [R=-0.463, P=0.012], V10Gy [R=-
0.465, P=0.011] and %-predicted OUEP: MCRD [R=-0.429, P=0.020], V5Gy [R=-0.477, 
P=0.009], V10Gy [R=-0.466, P=0.011]), respectively.  
The standard exercise test variables maximal HR and the rate-pressure product 
(RPP) (Max HR x Max systolic BP) inversely correlated with MCRD ([R=-0.441, 
P=0.017], [R=-0.486, P=0.008], V5Gy [R=-0.451, P=0.014], [R=-0.420, P=0.023], and 
V10Gy [R=-0.500, P=0.006], [R=-0.467, P=-0.011]), RPP only: V30Gy [R=-0.377 
P=0.044], V40Gy [R=-0.394, P=0.035, V50Gy [R=-0.515, P=0.004),respectively. 
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 Collectively, including peak VO2, the %-predicted peak O2 pulse showed the 
strongest correlations with MCRD and %heart volume exposed to RT dose. 
Interestingly, other key CPET variables(167) including the VE/VCO2 slope (R=0.259, 
P=0.175), exercise time (R=-0.352, P=0.061), HRR-1’ (R=-0.127, P=0.513), and the 
OUES (R=0.048, P=0.807) did not correlate with MCRD. 
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Table 14: Multivariate Analysis by Cardiac Limitation to Exercise. 
Variable R-Value Univariate P-value Multivariate P-value 
Radiotherapy Parameters 
Total Prescribed Dose (Gy) 0.209 0.42  
MCRD (Gy) -0.569 0.02  
MLRD (Gy) 0.017 0.95  
Cardiac Parameters 
MRI LVEF (%) 0.049 0.85  
ECV (%) -0.129 0.65  
Rest e’ 0.407 0.13  
E/e’ -0.482 0.06  
 e’exercise 0.700 0.04  
Exercise e’ 0.693 0.03 0.01 
Exercise E/e’ -0.576 0.08  
 E/e’exercise -0.139 0.70  
e’/DT ratio 0.344 0.19  
DFRI 0.783 0.01  
Exercise VTICO 0.103 0.78  
 VTICO exercise 0.633 0.07  
NTproBNP -0.601 0.01  
hs-cTnI -0.309 0.23  
hs-cTnT -0.598 0.01  
Galectin-3 0.174 0.50  
hsCRP -0.243 0.35  
Body Composition Parameters 
Weight (kg) -0.135 0.61  
BMI -0.059 0.82  
Waist Circumference -0.374 0.17  
W/H Ratio -0.364 0.18  
Fat Mass% -0.022 0.93  
Fat Mass Index -0.056 0.83  
Fat Free Mass% 0.054 0.84  
Fat Free Mass Index -0.199 0.45  
Ventilatory Parameters 
FVC 0.401 0.11  
FEV1 0.628 <0.01  
FEV1/FVC Ratio 0.400 0.11  
Direct MVV 0.488 <0.05  
 SPO2exercise -0.230 0.37  
All abbreviations are the same as Table 13. 
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Table 15: Multivariate Analysis by Pulmonary Limitation to Exercise. 
Variable R-Value Univariate P-value Multivariate P-value 
Radiotherapy Parameters 
Total Prescribed Dose (Gy) 0.000 1.00  
MCRD (Gy) 0.357 0.39  
MLRD (Gy) 0.638 0.17  
Cardiac Parameters 
MRI LVEF (%) -0.321 0.48  
ECV (%) 0.143 0.76  
Rest e’ 0.714 <0.05  
E/e’ -0.762 0.03  
 e’exercise 1.000 <0.01  
Exercise e’ 1.000 <0.01  
Exercise E/e’ -1.000 <0.01 <0.001 
 E/e’exercise -1.000 <0.01  
e’/DT ratio 0.381 0.35  
DFRI 1.000 <0.01  
Exercise VTICO -1.000 <0.01  
 VTICO exercise 1.000 <0.01  
NTproBNP -0.476 0.23  
hs-cTnI -0.719 <0.05  
hs-cTnT -0.381 0.35  
Galectin-3 -0.833 0.01  
hsCRP -0.381 0.35  
Body Composition Parameters 
Weight (kg) 0.143 0.74  
BMI 0.143 0.74  
Waist Circumference -0.238 0.57  
W/H Ratio -0.143 0.74  
Fat Mass% -0.190 0.65  
Fat Mass Index -0.190 0.65  
Fat Free Mass% 0.190 0.65  
Fat Free Mass Index 0.167 0.69  
Ventilatory Parameters 
FVC 0.548 0.16  
FEV1 0.595 0.12  
FEV1/FVC Ratio 0.690 0.06  
Direct MVV 0.762 0.03  
 SPO2exercise -0.741 0.04  
All abbreviations are the same as Table 13. 
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DISCUSSION 
 The results of this pilot study indicate aerobic exercise capacity defined as peak 
VO2 is markedly reduced (38% less than predicted normal values) in CA patients who 
have previously undergone thoracic radiation wherein the heart received significant RT 
dose. This exercise intolerance is multifactorial but our results indicate this is 
predominantly due to a cardiac dysfunction in a group of patients without a clinical 
diagnosis of CVD. The Doppler-stress echo-derived diastolic functional reserve index 
(DFRI) and the cardiac-biomarker NTproBNP are strong, independent predictors of 
peak VO2. Reduced aerobic exercise capacity is inversely associated with multiple 
indices of abnormal CV function using multiple imaging and biomarker analyses. 
Furthermore, the MCRD received during RT correlates with aerobic exercise capacity. 
This indicates CRF is sensitive to detect latent CV abnormalities in this cohort. This 
confirms the presence of impaired CRF in patients with CA who have previously 
undergone thoracic radiation wherein the heart received significant RT dose. The 
results also further show that the impairment in CRF shows a dose-dependent 
relationship with the radiation dose to the heart, and that impaired CRF is predominantly 
due to cardiovascular limitations in diastolic function with exercise (impaired diastolic 
reserve). 
 
Aerobic exercise capacity is reduced in CA survivors whom have previously 
undergone thoracic radiation wherein the heart received significant RT dose.  
The results of the current study demonstrate aerobic exercise capacity is 
markedly reduced in CA patients who have previously undergone thoracic radiation 
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wherein the heart received significant RT dose. Exercise capacity in this population has 
not been previously been characterized to this detail in reference to the RT regimen. 
The finding of reduced exercise capacity has been previously observed by others in the 
study of CA survivors who have anti-CA therapies.(166, 170, 174, 233, 234) Jones et al. 
evaluated peak VO2 in 47 post-menopausal hormone receptor+ breast CA women who 
all received anthracycline-based chemotherapy and 98% also underwent RT 
(mean=47±2.4 Gy) and observed a peak VO2 of 17.9±4.3 mL·kg-1·min-1 or 24% below 
age-gender matched healthy controls. Significant univariate predictors of peak VO2 
were BMI, glucose, CRP, and insulin. Associations with RT dose and/or MCRD was not 
reported.(233) 
In yet another study Jones et al. evaluated the CV risk profile including CRF in 26 
early-stage HER2+ breast CA patients (65% received RT) treated with adjuvant taxane-
anthracycline chemotherapy and/or trastuzumab.(174) Peak VO2 was 19.2  
mL·kg-1·min-1 and was significantly lower than controls. However, radiotherapy dose 
and/or MCRD was not reported. 
Burnett and colleagues sought to determine the proportion of breast CA survivors 
(at least 3-months post-chemotherapy or left-chest RT, 80% received anthracycline-
based chemotherapy, 40% received RT) with 2 or more CVD risk factors exhibiting a 
low VO2 max in 30 patients.(166) The mean VO2 was 25.4±5.3 mL·kg-1·min-1 which was 
commensurate to the 20th percentile threshold value for age-gender matched normative 
values with 77% having values below the 20th percentile value. Radiotherapy dose 
and/or MCRD was not reported. 
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A study by Adams et al. looked at CV status in 48 Hodgkin’s disease survivors 
who received mediastinal irradiation (40 [27.0-51.7] Gy).(234) The peak VO2 was 
significantly reduced (defined as < 20 mL·kg-1·min-1) in 30% of survivors. Furthermore, 
VO2 max was significantly correlated with increasing fatigue, shortness of breath, and 
decreased physical component scores on the short-form-36 HRQOL questionnaire. All 
subjects in this study underwent mediastinal RT, but relationships with dose and/or 
heart involvement was not reported. 
A review by Peel and colleagues developed normative values for peak VO2 in 
breast CA patients.(170) They identified 27 clinical trials involving a total of 1,856 
females (chemotherapy: n=78%, RT=56%, endocrine therapy= 33%) directly measuring 
pVO2 in the pre- or post-adjuvant setting. Radiotherapy dose and/or MCRD was not 
reported. The mean pVO2 prior to adjuvant therapy was 24.6 ml•kg-1•min-1, whereas the 
mean pVO2 post-adjuvant therapy was 22.2 ml•kg-1•min-1. This equated to a post-
adjuvant reduction in VO2 of -2.4 ml•kg-1•min-1or 10% lower. Compared with reference 
values the pre-adjuvant VO2 values were significantly lower (17%) than that of healthy, 
sedentary women (29.7 ml•kg-1•min-1) or 83% of predicted . In the post-adjuvant setting, 
pVO2 was 25% lower (75% of predicted) compared to healthy, sedentary values. 
A summarization of these prior studies in CA survivors is that reduced CRF is 
consistently observed in CA patients compared with normative values. Exercise testing 
occurred at different time points across the CA treatment continuum and has largely 
been cross-sectional in nature. They were treated predominantly with chemotherapy 
although a majority also having received adjuvant RT. The reduction in CRF appears to 
be more pronounced in the post-adjuvant period and is associated with a higher 
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prevalence of CVD risk factors. Reduced CRF is usually observed in the setting of a 
normal LVEF. The novelty of the current study lies in its detailed characterization of the 
exercise response in CA survivors and the contribution of significant RT dose to the 
heart.  
 
CRF in RT-treated chest CA survivors with significant heart dose is influenced 
predominantly due to cardiovascular dysfunction. 
 Cardiorespiratory fitness is determined by the components of the Fick equation 
where: VO2 = CO x a-vO2 difference. In normal healthy individuals and patients with 
systolic HF, CO is generally regarded as the primary determinant of CRF although this 
has not been consistently shown in those with HFpEF, the predominant HF phenotype 
in the breast CA patient.(235–237)  
 In the aforementioned study by Jones et al. the decreased peak VO2 in breast 
CA patients with a preserved LVEF (>50%) using impedance cardiography was due to a 
reduced CO response attributed to a blunted increase in SV with exercise compared 
with controls.(233) This was based on the finding that peak HR and a-vO2 difference 
was not different between the groups. The finding of a similar a-vO2 difference, 
however, may suggest impaired microvascular dysfunction and/or skeletal muscle 
abnormalities may also limit peak VO2 as oxygen extraction is directly proportional to 
muscle oxygen diffusion conductance and inversely related to CO.(238, 239)  
 Khouri et al. evaluated peak VO2, LV volumes, and CO using stress 2DE in 57 
female breast CA patients treated with doxorubicin-containing adjuvant therapy (79% 
received RT).(161) Peak VO2 was 20% lower in patients and stress echo SV and 
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cardiac index (CI) were lower than controls. Furthermore, the post-stress increase in CI 
predicted peak VO2. 
 A study by Koelwyn et al. evaluated arterial elastance (Ea), end-systolic 
elastance (Ees), and ventricular-arterial coupling (Ea/Ees) to determine the presence of 
vascular dysfunction following anthracycline-based chemotherapy.(175) In a cross-
sectional design, 30 ER+, HER2- breast CA survivors (77% underwent RT) and 30 age-
BMI-activity-matched controls underwent discontinuous CPET on an upright bicycle 
ergometer with 2DE images obtained at 25%, 50%, and 75% of peak work rate to 
calculate EDV, ESV, and LVEF. Central and peripheral vascular structure and function 
was also assessed. No significant differences were noted with resting measures of 
ventricular-arterial coupling between groups. The exercise Ea response was also not 
significantly different in survivors compared with controls. However, Ees was 
significantly reduced in survivors during exercise with a resulting elevated Ea/Ees ratio 
compared with controls at all exercise stages. Resting measures of LV systolic function 
were not different between CA survivors and controls, but LVEF was reduced at all 
three submaximal workloads in the survivor group. No significant differences between 
groups were found in regards to central and peripheral vascular structure and function. 
The results of this study indicate impaired ventricular-arterial coupling due to a reduced 
LV contractility in breast CA survivors at a mid-term follow-up period (>5-years) who 
were previously treated with anthracyclines with a majority having underwent adjuvant 
RT. 
Conversely, in a small pilot feasibility study (n=14) of comprehensive pulmonary 
evaluation following thoracic lung RT in childhood CA survivors, De and colleagues 
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described the prevalence of CPET abnormalities.(240) In 14 subjects (median time 
since RT=4.8 years, prescribed RT dose=21 Gy, MLRD=11.9 Gy), of which 11 
underwent CPET where nine patients demonstrated CPET abnormalities with the 
majority, seven (64%) being described as having a pulmonary limitation to exercise. 
However, they did not report CRF metrics, MCRD, or the status of CV function. 
These studies allude to seemingly normal cardiac function in CA patients who 
have undergone anti-CA treatments when referencing resting values but reveal 
unmasking of cardiac abnormalities when subjected to stress. The majority of studies 
examining exercise determinants in CA survivors to date have been cardio-centric with 
most of the emphasis being placed on indices of systolic function.(161, 174, 175) 
Presently, there is scant information on the contribution of diastolic dysfunction on CRF 
in CA survivors although breast CA survivors share a number of risk factors associated 
with HFpEF patients.(66, 104) Heart failure with a preserved ejection fraction is a 
heterogeneous syndrome although evidence of diastolic dysfunction is a critical 
component.(231)  
In an elegant animal model, Saiki et al. used cardiac radiation exposure to induce 
diastolic dysfunction with preserved ejection fraction.(241) Male rats were subjected to 
diffuse cardiac radiation at two different doses (10 and 20 Gy) using adeno-associated 
virus serotype-9 gene delivery of the rat sodium-iodide symporter gene followed by 
injection of radioactive Iodine-131 at 10-weeks age, were followed for five-months, and 
then underwent treadmill exercise testing, echo, hemodynamic catheterization, and 
tissue harvest. Radiation treated rats had reduced exercise capacity, increased LV 
diastolic stiffness, impaired myocardial relaxation, elevated filling-pressures, but similar 
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LVEF compared with controls. Post-hoc analysis showed evidence of a significant 
inverse linear trend between exercise capacity and radiation dose suggesting a dose-
response relationship. Exercise capacity was inversely correlated with mean circulatory 
filling pressure, positively correlated with microvascular density, and inversely correlated 
with LV fibrosis. Pathology revealed increased LV fibrosis, mild concentric 
cardiomyocyte hypertrophy, and reduced microvascular density. This study provides 
mechanistic insight into pathological link between HFpEF with diastolic dysfunction, RT 
exposure, and the resulting impairment of exercise capacity. 
 
Cardiac-biomarker NTproBNP and the diastolic functional reserve index (DFRI) 
are strong, independent determinants of peak VO2. 
 Natriuretic peptides (BNP, NTproBNP) are markers of ventricular wall stress and 
are produced endogenously to counteract the adverse effects of sympathetic nervous 
system RAAS activation in the presence of cardiac dysfunction.(242) Furthermore, 
natriuretic peptides are accurate in the diagnosis of HF, improve risk stratification of HF 
patients, improve patient management, may be helpful to screen for asymptomatic LV 
dysfunction in high-risk patients, and powerful predictors of outcome in predicting death 
and hospitalization in HF patients.(243, 244) The inactive amino-terminal portion of pro-
BNP, NTproBNP, is secreted in equivalent proportions to BNP, but has a longer half-life 
and may be more sensitive to detect early stage LV dysfunction.(245) Natriuretic 
peptides also inversely correlate with peak VO2 and are sensitive to change with 
interventions designed to improve CRF .(246–248) This supports the current study 
wherein NTproBNP was a strong, independent predictor of exercise capacity along with 
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indices of cardiac dysfunction in chest CA patients who had previously undergone RT 
with significant heart dose. 
 The DFRI has previously been shown to predict exercise capacity in individuals 
with exertional diastolic dysfunction with a decreased DFRI indicating exercise 
intolerance.(213, 214, 249) The utility of the DFRI is its ability to identify diastolic 
abnormalities not apparent at rest. The DFRI is the Doppler-echo derived product of 
e′rest•Δe′exercise. The early mitral annulus diastolic velocity (e’), a surrogate of myocardial 
relaxation, demonstrates a strong inverse correlation with the isovolumetric time 
constant (tau) a reference marker of LV relaxation and is less dependent upon 
preload.(250, 251) During exercise, augmentation of CO is achieved by increases in SV 
and HR. The tachycardia induced by exercise reduces diastolic filling time and the mitral 
inflow rate must increase to maintain or increase SV which can be accomplished by 
faster relaxation.(252) However, with diastolic dysfunction augmentation of relaxation is 
prevented as the HR increases during exercise.(253) The finding of reduced CRF and 
its strong association with DFRI in the present indicates impaired relaxation is driving 
the exercise intolerance. 
  
Mean cardiac radiation dose is inversely associated with CRF. 
 In the current study multiple imaging modalities and cardiac-biomarkers were 
utilized with the intent to identify CV abnormalities related to RT dose. Using CMR 
techniques (LVEF, LGE, ECV), Doppler echocardiography (systolic and diastolic 
parameters, Doppler spectra), and cardiac-specific blood-based biomarkers only the 
echo-derived early diastolic mitral annular velocity (e’), and  VTICO exercise were able to 
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demonstrate a significant relationship with the MCRD. On the contrary, multiple CRF 
variable demonstrated a significant relationship with RT doses. Moreover, this 
relationship was further strengthened when evaluating RT dose in those with a 
predominant cardiac limitation to exercise. Although a univariate predictor of peak VO2 
the MCRD was not an independent predictor in multivariate analysis. This indicates 
MCRD is not directly influencing CRF rather the pathophysiology associated with 
radiation exposure causes impaired relaxation evidenced by the reduced DFRI leads to 
exercise intolerance.   
 In a population-based case-control study of incident HF in female breast CA 
patients (MCRD=2.5 Gy, mean time post-RT=5.8 years), Saiki and colleagues 
demonstrated a dose-response relationship between MCRD and the incidence of 
HF.(104) The odds ratio (95%CI) for HF per log MCRD was 9.1 (3.4–24.4) for any HF, 
16.9 (3.9–73.7) for HFpEF, and 3.17 (0.8–13.0) for HFrEF.   
 In the Saiki et al. animal study, tau was linearly related to radiation dose.(241) 
Rats exposed to 10 Gy demonstrated longer relaxation times compared with controls 
and rats receiving 20 Gy had even longer relaxation times. 
 In another animal study by Mezzarroma et al., contractile reserve measured with 
an isoproteronol challenge decreased in a dose-dependent manner.(254) Mice exposed 
to two different doses (20 or 14 Gy) experienced a graduated attenuation of %LVEF 
change in the acute (72-hours) and late (4-months) stages compared to sham controls. 
 Wang and colleagues demonstrated a linear relationship between MCRD and the 
risk of cardiac events in lung CA patients who had undergone thoracic RT.(255) In 127 
patients with stage III NSCLC (ECOG status 0-1, prescribed RT dose=74 Gy, 
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MCRD=12.3 Gy, cardiac V5Gy = 36.5%) heart dose and baseline CVD each 
independently predicted the incidence of cardiac events.  
 
CRF is sensitive to detect subclinical cardiac dysfunction in CA survivors who 
have received thoracic radiation with heart involvement. 
 Traditionally, cardiotoxicity of anti-CA treatments has been defined by reductions 
in the LVEF. The change in LVEF, however, is insensitive to detect subtle declines in 
CV function and when it declines may manifest in overt HF with disabling symptoms and 
a poor prognosis.(256, 257) This has led to the active investigation of alternative 
imaging and blood biomarkers for the detection of early-onset cardiac injury including 
cardiac troponins, NTproBNP, echo tissue Doppler imaging, and CMR with LGE 
measurements.(258) Although not yet systematically evaluated to detect cardiotoxicity 
there have been increasing calls to recognize CPET and the measurement of peak VO2 
as a potential diagnostic tool and/or indicator of anti-CA related cardiac 
dysfunction.(258, 259) In the present study, peak VO2 demonstrated a dose-response 
relationship with RT dose that was strengthened in those with a predominant cardiac 
limitation to exercise. Peak VO2, a well-established indicator of prognosis in the cardiac 
patient(167), demonstrated strong correlations with NTproBNP, hs-cTnI, hs-cTnT, and 
multiple indices of diastolic function which are themselves known to predict 
prognosis.(244, 260) 
 
Is CRF a Therapeutic Target to Prevent or Reverse Cardiovascular 
Morbidity/Mortality in CA Survivors? 
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 Cardiorespiratory fitness is a global assessment of the interconnected responses 
involving the cardiovascular, pulmonary, skeletal muscle, hematopoietic, and 
neuropsychological systems to exercise.(186) The direct and indirect effects of anti-CA 
therapies have the potential to adversely influence all of these systems thus reducing 
CRF. Exercise training regimens have consistently been shown to have favorable 
effects on each of these integrated systems.(261) Furthermore, it has been 
demonstrated to be one of the few effective interventions to improve CRF in HFpEF 
patients which appears to be the predominant cardiac phenotype in CA patients.(104, 
238, 262) An elegant review by Scott et al. recently addressed the efficacy of exercise 
on cardiovascular toxicity in adult CA survivors.(263) The results indicate that at present 
the results of exercise training to mitigate cardiotoxicity are encouraging, but limited with 
most of the evidence coming from observational studies. 
 Neurohormonal blockade through the use of beta-blockers and RAAS inhibitors 
have been shown to decrease cardiac troponin and NTproBNP levels.(264) Evidence is 
accumulating for the use of beta-blockers (ß-blockers) in the prevention of 
cardiotoxicity.(265) Beta-blocker usage is associated with a lower incidence of HF 
following anti-CA treatment with anthracyclines and trastuzumab.(266) Animal studies 
allude to the cardio-protective effects of angiotensin-converting enzyme inhibitors (ACE-
I) in anthracycline cardiotoxicity.(267)  In an epidemiological cohort study of 142,990 
women with breast CA exposure to ß-blockers and ACE-I (defined as a filled 
prescription for such) resulted in a reduction of cardiotoxicity (adjusted hazard ratio 
(adj.HR) =0.77 (0.62-0.95) and all-cause mortality (adj.HR=0.79 [0.70-0.90]) compared 
with the non-exposed (never prescribed ß-blockers/ACE-I) group.(268) Angiotensin- 
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converting enzyme inhibitors also reduce the effects of radiation-induced 
nephropathy(269) although the benefit in RIHD has not been demonstrated. The 
independent predictive value of NTproBNP on peak VO2 in the current study suggests 
this may be viable target to improve cardiorespiratory fitness.  
Future Directions 
The observational nature of this study cannot prove a cause-effect relationship 
between RT dose to the heart and CRF. The demonstration of a direct cause-effect 
relationship would require a longitudinal study involving assessment of CRF and cardiac 
function both before and after administration of anti-CA therapies. Furthermore, a 
prospective interventional study would be required to ascertain if improvements in CRF 
translate into improvement of cardiac function and thus reduced CV risk status in this 
cohort.   
Limitations 
 The primary limitation of this study is its observational single-time point and thus 
leading to a cross-sectional assessment rather than longitudinal assessment of the 
disease. Therefore, despite the multiple correlations between cardiac variables, CRF, 
and RT dose a cause-effect link cannot be proven.  
There was significant heterogeneity in CA type and concomitant anti-CA 
systemic agent utilization investigated with this study. However, the unifying 
coexistence of a significant cardiac radiation dose threshold, but varying dose amounts 
based upon CA type and guideline-directed treatments (i.e. lower in breast CA vs. 
higher in lung CA) may have allowed detection of the observed dose-response 
relationship. 
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From a technical standpoint, when ascertaining organ-system limitation to 
exercise, no specific procedures were performed that directly measured peripheral 
vascular function or skeletal muscle characteristics both of which are known to 
contribute to exercise capacity.(270) There is also the potential confounding effects of 
patient medication use on the exercise response observed in this study. 
  
CONCLUSIONS 
 Impaired CRF is common in patients with CA who have previously undergone 
thoracic radiation wherein the heart received significant RT dose. The impairment in 
CRF shows a dose-dependent relationship with the radiation dose to the heart, and that 
impaired CRF is predominantly due to cardiovascular limitations in diastolic function 
with exercise (impaired diastolic reserve). Cardiopulmonary exercise testing is able to 
detect subclinical cardiotoxicity in chest CA patients treated with thoracic irradiation 
including a significant heart dose. This study warrants further investigation into 
radiation-induced exercise intolerance and the efficacy of interventions to improve CRF 
in this population.   
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